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Abstract

Ipomoeassin F is a flagship congener of a resin glycoside family that inhibits growth of many
tumor cell lines with only single-digital nanomolar IC50 values. However, biological and
pharmacological mechanisms of ipomoeassin F have been undefined. To facilitate exploration of
the biological and pharmacological properties, we performed sophisticate SAR (Structure–activity
relationship) studies of ipomoeassin F to understand its pharmacophore and structure properties so
that we can design favorable probes for further biological investigation. By applying appropriate
deviates that possess fluorescent groups and similar bio-activity, the target protein was found to
be localized in endoplasmic reticulum (ER). Through biotin affinity pull down and proteomics
studies, the target protein Sec61α (protein transport protein Sec61 subunit alpha isoform 1) was
successfully isolated and confirmed. The isolated protein validation by Western blot provides
convincing evidence to support the conclusion that Sec61α is the primary molecular target.
Subsequently, the binding mode between ipomoeassin F and Sec61α was proved to be noncovalent or reversible covalent binding with the help of reverse/delayed competition. Based on
competition result between ipomoeassin F and the derivatives with different activities, future
applications of those derivatives to search for detect Sec61α-specific bio-active compounds by
high throughput screening (HTS) are proposed. As a novel plant-derived carbohydrate-based
macrocyclic molecule, ipomoeassin F was proved to have an exclusive mode of action. The
successfully identification of its target protein Sec61α provides a new molecular tool to further
understand the Sec61α biological properties and its potential to be a new therapeutic target for
drug discovery. Most importantly, the information about this distinct mode of action would lead
to a new way to design and develop more effective anti-cancer drugs.
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CHAPTER 1. BACKGROUND AND INTRODUCTION

1.1. Cancer Epidemiology
1.1.1. Cancer
Cancer is one of the leading public health problems worldwide, and yet the most difficult
research area due to its intricate physiopathology. It is threatening public health as second cause
of death in the United States,1 leading to heavy burden on the medical care system and the society.

Figure 1.1 Estimated New Cancer Cases and Deaths by Sex, United States, 2019.1

1

From the data predicted, probability of being diagnosed with invasive cancer all through the
lifetime is as high as 37.7%-39.3%.1 According to the most recent data analysis,1 there will be
approximately 1,762,450 cancer cases diagnosed in the United States. That corresponding to more
than 4,800 new cases will be diagnosed every day. Despite great breakthroughs in modern surgery,
chemotherapy,

radiotherapy,

radiotherapy,

newly

established

targeted

therapies

and

immunotherapy significantly lessened morbidity and ameliorated survival over the past decades,2
cancer remains one of the most dangerous killers in the United States.3 It is estimated that 606,880
Americans will die from cancer in 2019, which is equivalent to nearly 1,700 deaths each day. From
the literature report (Figure 1.1), there will be 268,600 new cases of breast cancer to be diagnosed,
occupying 30% of all new woman cancers cases in 2019; and breast cancer is the second leading
cause of death after lung cancer in woman cancer cases.

1.1.2 Breast Cancer
Breast cancer is the leading cause of death among women aged 20 to 59.1 It was first
described as a breast bulging in ancient Egyptian medical papyri.4 Over the past few decades, the
overall cancer incidence rate in woman was relatively stable, however, breast cancer incidence
rates increased approximately 0.3% to 1.8% from 2006 - 2015.5 This trend is clearly illustrated by
data collected from 1975 - 2015 (Figure 2). Breast cancer survival rates vary significantly all over
the world with an 80% 5-year survival rate in developed countries which is below 40% in
developing countries.6
Breast cancer has been a worldwide critical public health problem for decades. The modern
breast cancer treatment began in 1880s, when Halsted applied surgical approach.7 With almost 140
years of continuous endeavor by innumerable physicians and scientists, prognosis of breast cancer
improved significantly. However, due to the complexity of breast cancer and drug development, it
2

is still one of the most life threating diseases to women. It is a never-ending fight against breast
cancer, extensive research is required to identify specific treatment and ameliorate its prognosis.
Cancer cell lines are commonly used as the primary in vitro experimental models to understand
cancer biology and molecular pharmacology of anticancer drugs.

Figure 1.2 Trends in Incidence Rates for Selected Cancers by Sex, United States, 1975 to 2015.1
As a heterogeneous disease, breast cancer consists of a series of clinical and molecular
distinct subtypes.8 Triple-negative breast cancer (TNBC) is a destructive type of breast cancer
which lacks expression of progesterone receptor (PR), human epidermal growth factor receptor 2
(HER-2) and estrogen receptor (ER), and the gene expression profile is often a basal-like cancer
cell line.9 TNBC is an invasive subtype and occupies around 15% of all invasive breast cancers.10
MDA-MB-231 cell line is a well-established human breast cancer epithelial cell line originated
from a pleura effusion of a Caucasian female breast cancer patient.11 It is commonly used as a

3

TNBC cell model characterized with highly aggressive, invasive and poorly-differentiated cancer,
endowing its great value in anti-cancer drug research.
MCF-7 is a commonly used breast cancer cell line established by Dr. Soule and his
colleagues in 1973.12 It was first isolated from pleural effusion of a breast cancer metastatic case.
MCF-7 is a luminal A molecular subtype cell line which is estrogen receptor (ER) - positive and
progesterone receptor (PR) - positive.13,14 It is a non-invasive cell line and proved to be a suitable
model cell line for anticancer drugs investigation.14,15
MCF-10 is a human breast epithelial cell line derived from s.c. mastectomy tissue from a
patient with fibrocystic disease.16 MCF-10A is an attaching immortal cell line which originated
from a mortal cell line MCF-10M. Electron microscopy revealed that MCF-10A has the same
characteristics of luminal ductal cells, moreover it maintains their epithelial cell characteristics.16
MCF-10A is considered as an important tool for investigating cell growth and carcinogenesis,16
therefore we include this cell line as a non-cancer control to evaluate compound selectivity among
breast cell derived cell lines.
In our bio-activity study, cytotoxicity of synthesized compounds was tested against the
highly invasive breast cancer cell line MDA-MB-231, non-invasive breast cancer cell line MCF7 and the breast epithelial cell line MCF-10A separately. Half maximal inhibitory concentration
(IC50) was calculated to evaluate compound potency, and the ratio between the IC50 from cancer
cell lines versus IC50 from epithelial cell was used to estimate selectivity of each compound.
1.2. Nature Product Ipomoeassins F
1.2.1. Nature product
Nature product consists of a significant amount of families with various chemical entities
that plays import roles in biological activities. Throughout human history, people have been

4

exploring nature for treatment of a wide spectrum of diseases regardless of their different location
and culture. Natural products have been the most widely used source for drug development,
especially in anti-infectives and anti-cancer studies.17-20 Over the past 75 years since the discovery
of penicillin, more than 23,000 natural products have been identified and characterized. 21 It is
reported that 60% of the 1500 FDA approved new chemical entities (NCEs) from 1981 to 2014
were natural products, derivatives or mimicked natural products.17 Among the 136 approved anticancer drugs, nearly 83% of the reagents were developed from natural products or were direct
derivates.22 Within the intense competition of drug development, more and more people are
realizing that there would be more chance of getting successful drugs from natural products rather
than collections of synthetic compounds. 23,24
Nowadays numerous incurable diseases have been conquered, however cancers, a series of
comprehensive systematic diseases, are still out of control due to the dilemma of killing cancer
cells together with normal cells damaged while applying anti-cancer drugs. This double-edged
sword effect originated from the lack of pinpointing effective target-oriented medicine. Therefore,
looking for an active natural product, identifying its druggable target and designing the
corresponding acting analogues without triggering off target effects, would be an ideal approach
for anti-cancer development.

1.2.2. Resin Glycosides and Ipomoeassin family
Resin glycosides, which are part of glycolipids or lipo-oligosaccharides family, consist of
complex resins (glycoresins).25 They are a group of compounds isolated from Convolvulaceae,
and widely used as traditional medicine to perform various biological activities including purgative,
haemolytic, laxative, antifungal, anti-bacterial and even cytotoxicity.26-30 All parts of
Convolvulaceae, including roots, leaves, stems, bulbs and flowers have been explored and used as
5

medication for different diseases.26,31 A large number of glycoconjugate natural products have
been identified to harbor anti-cancer bioactivity.32
The ipomoeassins, a representative of resin glycosides family, was first isolated from
Suriname rainforest by Kingston and his colleagues in 2005 from the leaves of Ipomoea
squamosa.33 This small class of six resin glycosides family is reported to have a range of biological
properties including antifungal, antibacterial and cytotoxicity.27,31 Kingston et al. isolated
ipomoeassin family A-E, and revealed their potency against an ovarian cancer cell line.33 While
resin glycosides are reported to be potent anti-cancer reagents based on their micromolar IC50
values against certain cancer cell lines, certain members in ipomoeassin family exhibit their anticancer toxicity at nanomolar IC50 values.34
NCI-60 was developed by US National Center Institute in the 1980s to maintain their own
collection of stable, differentiated cancer cell lines.21 The panel of 60 cell lines have been
employed to investigate the efficacy and specificity of all kinds of natural products. As the most
abundant in ipomoeassin family, ipomoeassin A was tested against NCI-60 cell lines and found to
have antiproliferation activity.34 What’s more, the activity pattern was found to be unmatchable
among known anticancer agents in National Cancer Institution (NCI) database.
Table 1.1. Structures and IC50 Values of Ipomoeassin A–F.34,35
Structure
Ipomoeas
sin
R1 R2 n
A
B
C
D
E
F

H
H
OH
OAc
OAc
H

Ac
H
Ac
Ac
H
Ac

IC50 (nM)
HeLa L-929 A2780 U937 HT-29

1
1
1
1
1
3

64 77.8
2500
1500 > 1000
32
135
4300 > 1000
7.4

6

500 20.2 46.1
400 134 396
2900
35
7.9 11.8
3300 163 393
36
2.6 4.2

MDA- H522MB-435 T1
42.6
108.9
2700
1070
19.9
23.2
1633
967
9.4
12.9

Two years after the extensive study on ipomoeassin family, Kingston group isolated another
family member ipomoeassin F, which possesses distinguished potency against multiple cancer cell
lines.35 According to previous in vitro cytotoxicity test, it inhibits cancer cells proliferation mostly
with IC50 value nanomolar range (Table 1.1). The impressive cytotoxicity is even more potent
than many clinical chemotherapeutic drugs. Interestingly, when we submitted our home made
ipomoeassin F for test against NCI-60 cell lines, the report not only confirmed its nanomolar
potency against couple of cell lines but also reflected its unique functional mechanism that was
different from all existing agents in NCI databases.36 The conclusion perfectly matches previous
research on ipomoeassin A.
Such high degree bioavailability of this newly discovered natural product endows its
potential promising candidacy for efficient anti-cancer drug development. Therefore, uncovering
the possible mode of action may pave a new road for anti-cancer development.

1.2.3. Target identification
An increasing number of natural products are well studied for potential therapeutical
candidates, however, their further development into application is always time consuming and
costly due to the limited understanding of the mechanism of action (MOA) and unexpected side
effects.37 Active small molecules perform their bioactivity through various ways of interaction
with their specific target in biological environment, As a result, identification of the pivot target
could significantly facilitate the understanding of their MOA as well as the unwanted side effects.37
It’s almost impossible to ignore the drug target whiling developing a mechanism-based drug.
Revealing the target can not only predict the future clinic efficacy and safety, but also provide clue
to understand and deal with side effects. For natural products, structural modifications through
synthesis are a widely used approach to uncover MOA, and may lead to potential clinical drug

7

development. Proteins are one of the most often targets, hence development of high-accuracy
research method will greatly improve the chance of identifying target proteins.

Figure 1.3. Target protein identification by affinity purification. (A) Workflow of target protein
identification by affinity purification and LC/MS. (B) Typical ABPP probe constitution.38
The combination of affinity chromatography and Mass spectrometry (MS) have been proved
to be successful way of unveiling target proteins. Based on specific bioactive interactions,
application of chemical proteomics and active-based protein profiling (ABPP) further improved
the rapid process and accurate target protein identification, minimizing the unspecific protein
disturbance.38-40 While working with chemical proteomics, molecular-protein interaction was
studied through applying various synthesized probes with functional moieties. This approach often
works together with MS to further push up greater precision and comprehensiveness than
traditional western blot.38,41 In ABPP chemical proteomics study, active functional probes are
design and synthesize by modification from compounds of interest. They identify the target protein
by probing covalent or strong non-covalent binding. Usage of ABPP coupling quantitative
8

chemical proteomics has played an important role in many insightful studies and proven to be a
powerful tool in identifying target identification.38,42
Probes (Figure 1.3B) designed for ABPP normally consist of three core elements: (1) reactive
group that specifically binds the target protein; (2) a traceable tag that enables affinity purification
(Figure 1.3A) and further image study; (3) a linker between reactive group and reporter tags. The
linker may act as an associated target protein purification or tracing facilitator by introducing
crosslinking or cleavable functional groups. Typical target protein identification by ABPP is
composed of cell or cell lysate incubation, probe-target protein complex isolation and target
protein identification.
1.3. Statement of the Problem
Since Kingston group isolated and reported the ipomoeassin family in 2005, more and more
scientists dedicate their research on exploring different properties of this potent anti-cancer agent.
Even through certain chemical and biological characteristics have been unveiled, the
understanding of the properties of this small family is still very limited.
Structure-activity relationship (SAR) study is one of the most frequently used as the first
approach to explore the MOA of a compound. By understanding the contribution of each
individual moiety to the bioactivity, appropriate modification could be introduced accordingly to
introduce favorable function groups with minimum disturbance to the original bioactivity. Probes
that maintain the biomedical properties of the compound of interest could be developed to further
define the MOA as well as the mechanism of side effects, endowing the possibility to produce
ideal drugs for serious diseases. From the data reported in the literature, some pieces of information
could be obtained about certain aspects of the structure-activity character of ipomoeassin F.
However, knowledge collected from available literature are far from sketching the contours of
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ipomoeassin F structure - activity relationship due to the lack of appropriate analogue library to
systematically study ipomoeassin F from all aspects.
As the most potent member of ipomoeassin family, ipomoeassin F has distinguished
cytotoxic effects on different cancer cells with unknown exclusive functional mechanism,
indicating the new compound has distinguished MOA by interacting with some novel molecular
targets. Deciphering the action mode of ipomoeassin F could probably open a new window for
manipulating the uncurbable cancer growth.
The goal of this project is to illustrate the contribution of each group of ipomoeassin F to its
potency, and to identify the corresponding target by using applicable probes, ultimately illuminate
the MOA of ipomoeassin F. Based on our research, we hope to apply the available discovery to
explore potential practical applications.
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CHAPTER 2. SAR STUDY AND PROBE EXPLORATION

The structures for ipomoeassin family were uncovered by spectroscopic data and chemical
degradation.1 The ipomoeassins are composed of a (1→2)--disaccharide as a core structure, and
hydroxylated fatty acid derivatives connecting disaccharide with different acylation patterns. The
core structure consists of a D-Glcp and D-Fucp-derivatives, while the peripherally connects with
cinnamate (cinn, C-4-Glcp), tiglate (tig, C-3Glcp) and aglycone. Within aglycone of ipomoeassins,
unlike for most resin glycosides, there is an oxygenation at C-4 position,2-3 a sterogeinc center at
C-11 position; and in some family members (ipomoeassin C-E), it contains a stereogenic center at
C-5 position.2,4
2.1. Structure-Activity Relationship study
For newly discovered compound, structure-relationship study (SAR) study is a classical yet
most rewarding medicinal chemistry method to understand the information of the compound
structure. With the help SAR study, potential pharmacophores would be well illuminated and
assigned in drug development. As a flagship congener of a resin glycoside family, ipomoeassin F
is an ideal candidate of systematic SAR study for developing novel anti-cancer drugs. This is not
only due to the distinguished potency of ipomoeassin F against cancer cell lines, but also because
of the limited understanding of exclusive MOA of this underexplored natural product. In the
systematical SAR study, all ipomoeassin F and its analogues are synthesized in our total synthesize
lab.

2.1.1. Structure-activity information from ipomoeassin family members
According to previous cytotoxicity data (Table 2.1), R1 in 4’-O site of D-fucose and R2 in C5 site of the fatty acid tether play a pivot role from the pharmacophoric point of view. This
15

conclusion is well elucidated by comparing the potency of ipomoeassin D and F with the rest of
the family members. Substitution on the two moieties could even lead to two orders of magnitude
potency change against different cancer cell lines. The available information from previous
cytotoxicity assay (Table 2.1) suggests that additional two methylene units in fatty acid of
ipomoeassin F result in lipophilicity increase, contributing to the potency of this amphiphilic
glycoconjugate.5 The conclusion that overall lipophilicity is vital to potency of the ipomoeassins
is further confirmed by comparing the IC50 value variation by the difference of OAc and OH in
R1(ipomoeassin D vs C), as well as in R2 (ipomoeassin A vs B, ipomoeassin D vs E).
Table 2. 1. Structures and IC50 Values of Ipomoeassin A–F.2,4
Structure
Ipomoeas
sin
R1 R2 n
A
B
C
D
E
F

H
H
OH
OAc
OAc
H

Ac
H
Ac
Ac
H
Ac

1
1
1
1
1
3

IC50 (nM)
MDA- H522MB-435 T1
20.2 46.1 42.6
108.9
134 396 2700
1070

HeLa L-929 A2780 U937 HT-29
64 77.8
2500
1500 > 1000
32
135
4300 > 1000
7.4

500
400
2900
35
7.9
3300 163
36
2.6

11.8
393
4.2

19.9
1633
9.4

23.2
967
12.9

2.1.2 Structure-activity information from characteristic structure modification
Some ipomoeassin family members are found to have impressive toxicity against multiple
cancer cell lines. Variation of peripheral oxygenation and acylation pattern in ipomoeassin
structure may trigger significant cytotoxicity fluctuation toward cancer cell lines.2 Ipomoeassins
possesses two exclusive structure features differ from other glycosides: (1) the carbohydrate core
structure is intensively connected to ester functionalities. (2) In the C-4 position of the fatty acid
chain, there is a ketone group. To clarify the functionality of those unique properties, we designed
and synthesized analogues 2.1-2.4 by removing those structure units one by one and then judging
the functionality by evaluating their potency gain or loss.
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A.

B.

2.2

2.1

2.4

2.3

Figure 2. 1. Structures of ipomoeassin F and its analogues 2.1-2.4. (A) Structure of ipomoeassin
F; (B) Structure of 2.1-2.4.
In the study of ipomoeassin family, the Fürstner group found that simultaneous migration
of tiglate and cinnamate damage the bioactivity.5 The importance of these two moieties was
further confirmed by our research data (Table 2.2).6 As we remove cinnamate (2.1) or tiglate
(2.4), the analogue potency dropped significantly (more than 1,000-fold change in MDA-MB231).
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Fürstner and his colleagues also reported that removal of the C-4 ketone in the fatty acid
chain impaired the potency.5 However, when we removed the carbonyl group in the hydrophilic
tether, analogue 2.3 almost retained its potency with a maximum 3-fold potency loss. Compared
to analogue 2.3, analogue 2.2 suffered relative more bioactivity loss when losing acetate group,
further verifying the hypothesis that increasing lipophilicity could enhance the bioactivity of
ipomoeassins. But the impact was limited at around 20-fold change, and the cytotoxicity of
analogue 2.2 against MCF-7 was almost retained (dropped 2-fold). All the information above
suggests the significance of influence on ipomoeassins potency in the order of cinnamoyl>
tigloyl>>acetyl>ketone.
Table 2. 2. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.1-2.4a

Ipomoeassin F
2.1
2.2
2.3
2.4

MDA-MB-231

MCF7

MCF-10A

6.3
7129.2
131.0
16.1
6848.0

36.4
9090.0
86.7
33.0
5929.0

5.3
NDb
297
30.7
ND

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%; b ND = not determined.

2.1.3. Structure-activity information from cinnamate and tiglate modification
Since both cinnamate and tiglate are confirmed to be the most important moieties that
contribute to ipomoeassins, we executed deep exploration within those two structure elements.
Both of the two moieties contain an α,β-unsaturated double bond, so we concluded that the
common structure double bond might contribute to the high cytotoxicity. Phenyl group, as a
structural constitution element in cinnamate, may also have something to do with its functionality.
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2.6

2.5

2.8

2.7

Figure 2. 2. Structure of ipomoeassin F analogues 2.5-2.8.
To verify these hypotheses, we designed and synthesized analogue 2.5 with cinnamate
double bond reduced, 2.6 with tiglate double bond reduced, 2.7 with the cinnamate double bond
missing and 2.8 with the phenyl group missing (Figure 2.2). The bioactivity change was evaluated
by comparing IC50 value against breast cancer cell line MDA-MB-231 and MCF-7 respectively.
Table 2. 3. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.5-2.8a

Ipomoeassin F
2.5
2.6
2.7
2.8

MDA-MB-231

MCF7

MCF-10A

6.3
980
429
930
4500

36.4
2560
477
2890
3930

5.3
NDb
ND
ND
ND

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%; b ND = not determined.
Through cytotoxicity screening, the importance of double bond in cinnamate and tiglate is
uncovered (Table 2.3). As expected, removing any of the double bonds in cinnamate or tiglate
result in significant potency loss. But the cytotoxicity loss of reducing or removing cinnamate
(dropped 150-fold in 2.5 and 2.7) is more obvious than that of tiglate (dropped 66-fold in 2.6),
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indicating the cinnamate double bond may play more important role than tiglate double bond in
cytotoxicity. When we removed the phenyl group by substituting cinnamate with tiglate, the
analogue 2.8 suffered dramatically potency loss (dropped almost 700-fold), suggesting the pivot
role of aromatic group in biological activities.
Since cinnamate was shown to be more important than tiglate and both of these two α,βunsaturated esters were critical to retain ipomoeassin F potency, we were interested to know
whether substituting tiglate with cinnamate could increase or maintain the cytotoxicity and
whether those two moieties were interchangeable. To answer these follow-up questions, we
designed another two analogues 2.9 and 2.10 (Figure 2.3).

2.9

2.8

2.10

Figure 2. 3. Structure of ipomoeassin F analogues 2.8-2.10.
A.
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B.

Figure 2. 4. Viability curves of ipomoeassin F and analogues 2.8, 2.9, 2.10 in breast cancer cell
lines: (A) Cytotoxicity in MDA-MB-231 cell line; (B) Cytotoxicity in MCF-7 cell line. (72h
incubation)
Cytotoxicity evaluation7 indicates any of the changes on these two groups leads to significant
potency loss (Figure 2.4). The cytotoxicity data further confirmed the irreplaceable role of
cinnamate and tiglate, and also suggested the optimal combination for ipomoeassin F to perform
its biological activity to be the aromatic α,β-unsaturated ester at C-4-Glcp and an aliphatic α,βunsaturated ester at C-3-Glcp.

2.1.4. Structure-activity information from hydrophilic moieties modification
Ipomoeassin F is an amphiphilic glycoconjugate with only two hydrophilic hydroxyl groups
at 3-OH-Fucp and 2-OH-Glcp. To better understand the function of the two groups in the molecular,
we designed analogue 2.11 and 2.12 by introducing acetylation to the corresponding site and then
evaluate the cytotoxicity on breast cell lines (Figure 2.5).
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2.12

2.11

Figure 2. 5. Structures of ipomoeassin F analogues 2.11-2.12.
The cytotoxicity data indicates that amphiphilic character is a one of the important factors
that retain the molecular biologic activity (Table 2.4). The two hydrophilic sites may serve as an
exit tunnel to the aqueous environment and maintain the conformational stability. With a
hydrophilic hydroxyl group left at 2-OH-Glcp, analogue 2.11 still exhibit strong potency even its
potency decreases compared with ipomoeassin F. But analogue 2.12 on the other hand, totally lost
its biological activity, which may be caused by poor aqueous solubility due to lack of hydrophilic
group.
Table 2. 4. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.11-2.12a

Ipomoeassin F
2.11
2.12

MDA-MB-231

MCF7

MCF-10A

6.3
16.5
>10,000

36.4
216
>10,000

5.3
24.0
NDb

a

The data were obtained from at least two independent experiments with the same condition,
and the standard errors are within 20%; b ND = not determined.

2.1.5. Structure-activity information from aglycone modification
2.1.5.1. Impact of stereogenic center C-11 on ipomoeassin F bioactivity.
Within aglycone of ipomoeassin F, there is a unique stereogenic center at C-11 position. We
hypothesized the exclusive structure may have a close relationship with molecular cytotoxicity,
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switching C-11S of ipomoeassin F into C-11R could inevitably impair its biological activity. To
verify the hypothesis, we synthesized epimer analogue 2.13 and test its cytotoxicity against breast
cancer cell lines (Figure 2.6).

Figure 2. 6. Structures of ipomoeassin F and its C-11R epimer 2.13.
As expected, the cytotoxicity result perfectly supported the hypothesis.8 Cytotoxicity of
constructed C-11R epimer leads to a 38-fold potency loss in MDA-MB-231 cytotoxicity assay
compared with C-11S configuration of ipomoeassin F, giving the conclusion that C-11S is a
favorable configuration for the impressive cytotoxicity.
Table 2. 5. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its epimer 2.13a

Ipomoeassin F
2.13

MDA-MB-231

MCF7

MCF-10A

6.3
240.2

36.4
830.7

5.3
159.2

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%.
2.1.5.2. Impact of open-chain aglycone on ipomoeassin F bioactivity.
Other than chiral center, cyclic structure framework is another key character of ipomoeassin
F. In literature, people believe cyclic structure framework is critical in retaining macrocycle
biological activities.9-10 In order to clarify whether this hypothesis is applicable to the macrocyclic
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skeleton of ipomoeassin F, we designed an open-chain analogue 2.14 and its terminal reduced
analogue 2.15 to expel the disturbance introduced by terminal double bond (Figure 2.7).

2.14

2.15

Figure 2. 7. Structures of ipomoeassin F analogues 2.14 and 2.15.
However, the cytotoxicity result doesn’t quite follow the hypothesis. Open chain analogue
2.14 retained good potency even though experience some limited cytotoxicity loss (Table 2.6).
While reducing the double bond, the analogue 2.15 recovered the cytotoxicity obviously, leaving
the impression that integrity of macrocyclic structure is not the key requirement for maintaining
high biological activity in ipomoeassin F.
Table 2. 6. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.14-2.15a

Ipomoeassin F
2.14
2.15

MDA-MB-231

MCF7

MCF-10A

6.3
59.1
18.8

36.4
124
78.2

5.3
151
11.8

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%.
Cytotoxicity data conveyed another interesting piece of information that interruption of the
ring structure of ipomoeassin F evidently improve its selectivity. Before opening the cyclic
structure, the selectivity index (IC50 values in MCF-10A / IC50 in MDA-MB-231) is 0.84. But
when the ring structure is opened, this index increases dramatically to 2.55. However, as double
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bond in open chain reduced, the index drops back to 0.63. The variation of selectivity index
suggests double bond in open chain terminal increase the selectivity of this macrocyclic glycoside,
providing valuable information for future anti-cancer drug development.
2.1.5.3. Impact of cyclic structure size on ipomoeassin F bioactivity.
Although the cytotoxicity data of open chain analogues is not aligned with literature, the
import role of cyclic structure in ipmoeassin F biological activity is not ignorable. Even so, the
influence of cyclic structure size to ipomoeassin F potency is not fully understood. So, we try to
change the ring size by adding (2.16) or chopping (2.17) one or two members to the skeleton and
explore the impact on its cytotoxicity.

Figure 2. 8. Structures of ipomoeassin F and its analogues 2.16 and 2.17.
Since cyclic structure is one of the exclusive characters, the modification on the size lead to
evident cytotoxicity difference (Table 2.7). Interestingly, as aglycon ring size becomes larger,
molecular potency increases 4-fold. On the other hand, decreasing the ring size gives rise to even
10-fold potency loss. A possible explanation for the bioactivity change is that as the size of aglycon
increase, the molecular becomes easier to be incarcerated after binding to the target protein
functional pocket, facilitating compound-target protein interaction. The result not only firmly
supports the critical role of cyclic structure framework in maintaining biological activities, but also
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provides solid evidence for the conclusion that overall lipophilicity is vital to maintain potency of
ipomoeassin F.
Table 2. 7. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.16-2.17a

Ipomoeassin F
2.16
2.17

MDA-MB-231

MCF7

MCF-10A

6.3
1.3
67.8

36.4
9.1
291.6

5.3
0.6
98.6

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%.

2.1.6. Structure-activity information from fucose modification
D-Glcp and D-Fucp connecting with functional groups constitute the core structure of
ipomoeassin F. According to the structure-activity relationship discussed above, certain
modifications around D-Fucp didn’t significantly diminish the molecular cytotoxicity. To further
explore the biological contribution of D-Fucp, we plan to truncate the whole fucose and design
monosaccharide analogues 2.18 and 2.19 (Figure 2.9).

2.18

2.19

Figure 2. 9. Structures of ipomoeassin F analogues 2.18 and 2.19.
The biological activity of analogues was evaluated against two breast cancer cell lines MDAMB-231 and MCF-7.11 Compared with ipmoeassin F, the two monosaccharides almost lost any
inhibition of cell proliferation (Figure 2.10). Without doubt, D-Fucp is indispensable in the
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bioactivities of impomoeassin F. Accompanied with the information that modification of
peripheral groups could cause very limited potency loss, it is not hard to come to the conclusion
that the existence of D-Fucp provides stability to maintain the appropriate confirmation of
ipomoeassin F structure, so it can work properly with the target protein.
A.

B.

Figure 2. 10. Viability curves of ipomoeassin F and analogues 2.18 and 2.19 in breast cancer cell
lines: (A) Cytotoxicity in MDA-MB-231 cell line; (B) Cytotoxicity in MCF-7 cell line. (72h
incubation)
2.1.7. Summary of structure-activity relationship study
In conclusion, by deliberate design, synthesis and cytotoxicity screening, we built up a
systematic analogue library of ipomoeassin F. With the help of complicated structure modification
vs cytotoxicity variation, the importance of each moiety was illuminated. The influence
significance

of

different

groups

can

be

summarized

at

the

rank

of

D-

Fucp >cinnamate >tiglate >alkene in cinnamate > alkene in tiglate > acetate > 3-OH-Fucp >cyclic
skeleton ≈ ketone (Figure 2.11).
As an amphiphilic glycoconjugate, both hydrophobic groups and hydrophilic groups are
indispensable for ipomoeassin F to perform its cytotoxicity. Hydrophilic groups, work as a vessel,
help the overall molecule stay soluble in an aqueous environment so that it could be transported
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into the cell. Hydrophobic groups, work as anchors and functionality portions, facilitate
ipomoeassin F anchoring inside hydrophobic binding pocket and interact with target protein in the
hydrophobic environment. Therefore, increasing hydrophobicity appropriately would favor its
interaction with target protein. However, introduction of hydrophobicity by blocking hydrophilic
moieties will inevitably damage the potency due to the significant aqueous solubility loss.

Figure2. 11. Cytotoxicity loss by pharmacophore editing.
All characteristic structures work together to maintain the distinguish potency of
ipomoeassin F. Chiral center C-11R keeps ipomoeassin F function at an optimal configuration;
ring structure aglycon helps the molecular stay firmly inside binding pocket facilitating further
interaction with protein domains. Opening the cyclic structure retains cytotoxicity probably by
limited conformational disturbance, and the modification evidently uncovered selectivity increase,
providing a new approach for clinical drug development. The dramatical cytotoxicity disturbance
along with modification of two α,β-unsaturated esters cinnamate and tiglate suggests that they may
play important role in interacting with the target protein by covalent binding or strong non-valent
interaction, directing a promising way for further MOA study and target protein identification.
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2.2. Probe Design and Selection
Chemical probe is a series of modified molecular maintain original drug structural and bioactive similarity but has certain key chemical and structural differences.12 The introduced key
functional groups are essential to illustrate the unknown compound-cell/bio-molecular interaction
and support unbiased interpretation of biological experiments. Developing appropriate chemical
probe tool kit more than once has been documented to be beneficial towards action mode
exploration and drug development.
Scientists at Pfizer Inc recently published the four pillars philosophy (Figure 2.12) in
directing successful drug development program by retrospective analyzing 44 drug programs and
2 clinical trials.13 Pillar 1 involves the efficacy exposure of probes at the expected site of action.
The first pillar confirms cellular permeability of the probes by evaluating the pharmacologically
relevant concentrations at the target site, therefore rule out the possibility that the response is due
to unspecific binding. The pillar 2 proves target engagement and is the most challenging validation.
But appropriate strategy approach such as activity-based proteomics profiling, fluorophore
introduction would facilitate target identification and validation. Pillar 3 and pillar 4 further
confirm the pharmacokinetic and pharmacodynamic properties of a drug to be developed and
phenotype disturbance after probe application. Probes with poor access to the site of action would
lead to the lack of pharmacological (pillar 3) or phenotypic (pillar 4) response, resulting in false
negative result. According to their analysis, failed projects often are not able to fulfill some or all
the four pillars.
With the employment of cytotoxicity screening, the different moiety properties of
ipomoeassin F is well established. According to information collected from SAR study, most vital
factors for maintaining ipomoeassin F cytotoxicity are position of cinnamate and tiglate, existence
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of the two α,β-unsaturated double bond, existence of aromatic ring structure in cinnamate and the
complete D-Fucp structure. In order to avoid disturbing molecular potency at minimum extent,
we design our probe by introducing functional groups at para position of the aromatic ring structure
to push introduced moieties away from core structure as far as possible.

Figure 2. 12. The four pillars of cell-based target validation using chemical probes.13
2.2.1. Probes for stepwise target protein identification
Active-based protein profiling (ABPP) is a typical approach to identify target protein. Probes
for ABPP typically consist of an active site, a linker and a traceable tag. These three constituents
greatly facilitate the target identification efficacy, however, too many structures in the probe on
the other hand causes steric hinderance between probe and the target protein, influencing the
chance of successfully binding to expected targeting site.
To overcome this disadvantage, stepwise click chemistry is employed for target identification.
In our project, we designed probe 2.20 by introducing alkyne into para position of benzene ring.
According to our SAR study, α,β-unsaturated double bond is one of the most critical structure that
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help maintain molecular cytotoxicity. As a result, a new analogue 2.21 with all double bonds
reduced would be expected to be inactive, so that it can be used as an ideal negative control.
As expected, slight modifications on aromatic ring did not disturb the biological activity
too much (Figure 2.13B), indicating the change have little impact on MOA of ipomoeassin F.
A.

B.

Figure 2. 13. Structure and cytotoxicity of ipomoeassin F analogues 2.20 and 2.21. (A) Structure
of 2.20 and 2.21. (B). Viability curve of 2.20, 2.21 and ipomoeassin F in MDA-MB-231 and MCF7 (72h incubation).
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It is a high probability that 2.20 could bind the same target, hence introduction of traceable tags
like fluorophore or biotin by click chemistry reaction following 2.20 specifically binding the
target protein may provide great chance to capture and trace the target protein (Figure 2.14).
Being an inactive analogue, 2.21 is a perfect corresponding side by side negative control of any
probe that labels target protein for identification by introducing function groups into 2.21.
A.

B.

=

Figure 2. 14. Diagram of stepwise target protein identification. (A) Target protein labelling; (B)
Introduction of traceable moieties for protein isolation and identification.
2.2.2. Probes for ABPP by fluorophore reporter
Fluorophore is commonly used strategies for tracking biological action mode not only in
subcellular level but also in molecular level studies due to its high sensitivity. To make good use
of the great advantage, we designed fluorescent probes 2.22 - 2.28 (Figure 2.15).
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2.23
2.2
2

Figure 2. 15. Structure of ipomoeassin F analogues 2.22-2.28.

Based on cytotoxicity screening in breast cancer line MDA-MB-231 and MCF-7, analogue
2.22, 2.23, 2.26, 2.27 were expelled due to significant potency loss (Table 2.8). Both coumarincoupled probe 2.24 and NBD-coupled probe 2.28 retained substantial cytotoxicity with 2.28 being
even more potent than ipomoeassin F. Unfortunately, 2.28 underwent photobleaching very easily
and could not be used for imaging studies. In contrast, 2.24 gave a rather weak fluorescent signal,
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presumably due to an internal photo-induced electron transfer effect combined with its shorter
excitation maximum (365 nm). Fluorescent signal from probe 2.25 was strong and stable in
different situation, and therefore was selected for further cell imagine studies.
Table 2. 8. Cytotoxicity (IC50, nM) of Ipomoeassin F and its Probes 2.22-2.28a

Ipomoeassin F
2.22
2.23
2.24
2.25
2.26
2.27
2.28

MDA-MB-231

MCF7

MCF-10A

6.3
5,500.3
8,547.6
8.9
253.4
7,225.5
1,270.6
2.8

36.4
5,825.1
10,565
172.2
172.2
>25,000
>25,000
21.1

5.3
NDb
ND
11.3
133.8
ND
ND
2.0

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%; b ND = not determined.

2.2.3. Probes for ABPP by affinity tag reporter
Biotin affinity pull down experiment is a widely used approach for target protein purification
and identification. The strategy is based on strong non-covalent binding between biotin and
streptavidin, specifically reserving target protein that forms complex with biotin containing probes.
Since high specificity is a great advantage of biotin affinity target protein identification, we
designed probes 2.29 - 2.33 (Figure 2.16). 2.29 is expected to be an active probe with short linker,
its reduced form 2.30 is expected to be corresponding negative control.
Accordingly, probe 2.31 and probe 2.33 are designed to be active probes with long linkers.
In order to better exclude noise signal from non-specific binding protein, we introduced a
photocleavage moiety into the linker. Probe 2.32, a reduced form of 2.33, was designed to be the
corresponding negative control.
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Figure2. 16. Structures of ipomoeassin F analogues 2.29 - 2.33.
As expected, active analogues 2.29, 2.31 and 2.33 keep the cytotoxicity loss within 5-fold
(Table 2.9). Among these potential applicable probes, 2.31 almost withholds disturbance of
structure modification, suggesting the high probability that it shares identical target protein as
ipomoeassin F. Probes 2.30 and 2.32 were proved to be perfect negative controls that have no
biological activity against test cells.
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Table 2. 9. Cytotoxicity (IC50, nM) of Ipomoeassin F and its Probes 2.29-2.33a

Ipomoeassin F
2.29
2.30
2.31
2.32
2.33

MDA-MB-231

MCF7

MCF-10A

6.3
29.5
>25,000
7.0
>25,000
24.1

36.4
187.4
>25,000
19.8
25,000
225.3

5.3
21.7
NDb
5.1
ND
21.9

a

The data were obtained from at least two independent experiments, and the standard errors
are within 20%; b ND = not determined.

2.2.4. Summary of Probes design and selection.
Active based protein profiling (ABPP) is a widely accepted as an efficiency strategy for
target protein identification. According to our systematic SAR study of ipomoeassin F, we
designed and tested probe 2.20 and its corresponding negative control 2.21 for stepwise ABPP.
We designed a couple of fluorescent probes and picked up 2.25 for future study because of its
acceptable potency, strong fluorescent intensity and fluorophore stability. We also designed biotin
probes and verified their applicability from their cytotoxicity. 2.29 and 2.30 are selected to be short
linker pairs for affinity purification; 2.31 is selected to be an ideal candidate for MOA study; 2.32
and 2.33 are selected to be long linker pairs for affinity purification.
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CHAPTER 3. IPMOEASSIN F TARGET PROTEIN IDENTIFICATION AND
VALIDATION
3.1. Abstract
Ipomoeassin F is a potent natural cytotoxin that inhibits growth of many tumor cell lines with
single-digit nanomolar potency by an undefined mechanism. However, its biological and
pharmacological properties have remained largely unexplored. Building upon our earlier
achievements in total synthesis and medicinal chemistry, we used chemical proteomics to identify
Sec61α (protein transport protein Sec61 subunit alpha isoform 1), the pore-forming subunit of the
Sec61 protein translocon, as a direct binding partner of ipomoeassin F in living cells. The
interaction is specific and strong enough to survive lysis conditions, enabling ipomoeassin F to
pull down Sec61α from live cells, yet it is also reversible as judged by fluorescent streptavidin
staining and reverse competition. Sec61α provides the central subunit of the ER protein
translocation complex, and the binding of ipomoeassin F results in cell proliferation inhibition.
Therefore, ipomoeassin F represents the first plant-derived, carbohydrate-based member of a novel
structural class that offers new opportunities to explore Sec61α function and to further explore its
potential as a therapeutic target for drug discovery.

3.2. Introduction
Historically, natural products have significantly contributed to the development of drugs for
human disorders,1 most notably as anticancer chemotherapeutics.2 Structurally and functionally
unique natural products also provide a spectrum of valuable chemical tools for examining
biological systems in translational biomedical research.3,4 To continue our battle against various
unsolved problems of human health, including those arising from drug resistance, it is crucial to
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systematically investigate underexplored areas of existing chemical space such as those offered by
bioactive natural products with unique structures and/or mechanisms.5
Resin glycosides, also called glycoresins, are a large collection of amphiphilic glycolipids
isolated from the morning glory family of plants,6 and these compounds are considered active
ingredients of many morning glory-based traditional medicines that are used worldwide. Resin
glycosides consist of a differently-acylated oligosaccharide glycosylated with a mono- or
dihydroxy C14 or C16 fatty acid, with more than 300 family members discovered to date. Through
an ester bond, the fatty acid chain is usually folded back to form a macrolactone ring of various
sizes spanning one or more carbohydrate units. Because of their unique macrocyclic architecture
with embedded carbohydrates, and their broad spectrum of biological activities exhibited in
phenotypic screens, resin glycosides have attracted considerable attention from the synthetic
chemistry community, but not much beyond.7-9
In 2005, a new family of glycoresins, ipomoeassins A–E, was isolated from the leaves of
Ipomoea squamosa found in the Suriname rainforest and shown to inhibit the proliferation of
A2780 human ovarian cancer cells.10 Among these compounds, ipomoeassin D (Figure 1)
displayed the greatest potency with an IC50 value of 35 nM. Two years later, a new member of the
family, ipomoeassin F (Figure 1), was isolated and showed a cytotoxicity comparable to
ipomoeassin D.11 Because of their promising antiproliferative activity and unique molecular
skeleton with carbohydrates being part of the macrocycle, these newly discovered natural
glycoconjugates quickly inspired synthetic chemists, including ourselves, to tackle their total
syntheses.12-16 Subsequently, ipomoeassin F was confirmed to be the most cytotoxic resin
glycoside discovered to date with single-digit nanomolar IC50 values against several cancerderived cell lines.13 Intriguingly, ipomoeassins A and F (see Figure 1) have distinct cytotoxicity
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profiles, as revealed in the NCI 60-cell lines screen, suggesting that the ipomoeassins may possess
an unusual mode of action.16,17 On this basis, ipomoeassin F is a very promising candidate for
molecular probe and chemotherapeutic development; however, the absence of knowledge about
the cellular targets of ipomoeassin F has significantly impeded such efforts. To overcome this
challenge, after improving our understanding of the structure–activity relationship (SAR) of
ipomoeassin F through medicinal chemistry studies,18-20 we employed a chemical proteomics
approach to identify its binding partner(s) in human cells. Here we describe the evolution of our
chemoproteomic studies that enabled the discovery of Sec61α (protein transport protein Sec61
subunitalpha isoform 1) as a primary molecular target of ipomoeassin F, and our subsequent
mechanistic investigations which validate this component as a key target. We define the inhibitory
effects of ipomoeassin F on Sec61-mediated bioactivity within endoplasmic reticulum (ER),
corroborating our contemporaneous observations of the potent inhibition of cellular secretion by
ipomoeassin F.

Figure 3. 1. Structures of ipomoeassins A, D, and F.
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3.3. Results and Discussion
3.3.1. Proteomics Evaluations of Chemical Probes derived from Ipomoeassin F.
Michael acceptor systems are present in many electrophilic natural products, allowing the
formation of covalent adducts with bio-macromolecules, which are often responsible for their
biological activities.21 Because of significant activity loss (up to 160-fold) after reducing one of
the two double bonds in the α,β-unsaturated esters to a single bond,22 we hypothesized that the
cinnamate and/or the tiglate (Figure 3.1) may enable irreversible binding between ipomoeassin F
and its biological target(s). Therefore, we initially designed and synthesized a potential activitybased probe23-25 3.1 (Figure 3.2) by introducing a small propargyloxy group to the para position of
the benzene ring.

Figure 3. 2. Structure of ipomoeassin F analogues 3.1-3.3.
With probe 3.1 in hand, we conducted activity-based protein profiling experiments for target
identification both in the soluble fraction of cell lysates made from MDA-MB-231 breast cancer
cells and live MDA-MB-231 cells. Unfortunately, after in situ click chemistry with a fluorescent
rhodamine azide 26, we detected no differences in labeled proteins between negative control (lane
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1), probe 3.1 (lane 2), and probe 3.1 plus ipomoeassin F (competition; lane 3) (Figure S2A), while
an unrelated probe used as a positive control for pulldown gave clear signals (Figure S2A, lanes 4
and 5). We considered two possible explanations for this negative result: firstly, ipomoeassin F is
not a covalent protein modifier; secondly, target proteins of ipomoeassin F are in low abundance.
Due to the dramatic loss in activity with alkene-reduced compounds,22 we favored the second
possibility.
Table 3. 1. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its Probes 3.1-3.7a
MDA-MB-231b

MCF7

MCF-10A

Ipomoeassin F
6.3
36.4
5.3
3.1
6.3
22.2
9.6
3.2
29.5
187.4
21.7
3.3
7.0
19.8
5.1
3.4
24.1
225.3
21.9
3.5
> 25,000
> 25,000
NDc
3.6
> 25,000
> 25,000
ND
3.7
253.4
172.2
133.8
a
The data were obtained from at least two independent experiments, and the standard errors
are within 20%; b See Figure S1 for IC50 curves; cND = not determined.
With probe 3.1 in hand, we conducted activity-based protein profiling experiments for target
identification both in the soluble fraction of cell lysates made from MDA-MB-231 breast cancer
cells and live MDA-MB-231 cells. Unfortunately, after in situ click chemistry with a fluorescent
rhodamine azide 26, we detected no differences in labeled proteins between negative control (lane
1), probe 3.1 (lane 2), and probe 3.1 plus ipomoeassin F (competition; lane 3) (Figure S2A), while
an unrelated probe used as a positive control for pulldown gave clear signals (Figure S2A, lanes 4
and 5). We considered two possible explanations for this negative result: firstly, ipomoeassin F is
not a covalent protein modifier; secondly, target proteins of ipomoeassin F are in low abundance.
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Due to the dramatic loss in activity with alkene-reduced compounds,22 we favored the second
possibility.
In order to enrich for relatively low abundance cellular proteins, we next synthesized a biotinlabeled analogue 3.2 of ipomoeassin F by reacting the alkyne probe 3.1 with biotin azide 27 under
chemo-selective copper-catalyzed alkyne-azide coupling (CuAAC) conditions.28 The synthesis
was successful in producing biotin probe 3.2 that remained cytotoxic (Table 3.1), showing only
~5-fold decrease. After incubating 3.2 with either detergent solubilized cell lysate or intact cells,
we ued streptavidin beads to recover the biotin probe 3.2-bound proteins followed by
electrophoresis and silver staining of the captured material. However, no proteins were selectively
enriched by probe 3.2 (Figures S3A and S3C, lanes 1 to 3), nor was any enrichment apparent when
these samples were probed using a fluorophore-labeled streptavidin (Figure S3B, lanes 1 to 3).
We hypothesized that if the target protein(s) of ipomoeassin F is of relatively low abundance,
then endogenously biotinylated proteins could outcompete, and thereby mask, any positive signal.
To minimize interference from endogenously biotinylated proteins, we synthesized a new biotin
probe 3.3 (Figure 3.2) containing a photo-cleavable nitrobenzene moiety29 by coupling the alkyne
analogue 3.1 with the biotin azide fragment containing an o-nitrobenzyl photolabile linker, the
latter synthesized by modifying previously reported procedures26-28 . Notably, the capacity of 3.3
to inhibit cancer cell proliferation was close to that of parental ipomoeassin F (Table 3.1), despite
the large size of the appendage at the para-position of the cinnamate benzene ring. We then used
probe 3.3 to label target proteins in live MDA-MB-231 cells, performed a streptavidin pulldown
on the resulting cell lysate and selectively released bound proteins by UV photocleavage. When
the resulting products were analyzed by SDS-PAGE, probe 3.3 strongly enriched a ~40 kDa
protein and, to a lesser extent, a second protein of ~100 kDa (Figure 3.2A, lane 2, red arrows),
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both of which were absent from the negative control (Figure 3.3A, lane 1). In support of their bona
fide interaction with 3.3, these two proteins were lost when a 100-fold excess of unmodified
ipomoeassin F was included during the incubation (Figure 3.3A, lane 3). Because no proteins were
selectively recovered with probe 3.3 when it was incubated with detergent-solubilized (1% NP40
and 0.25% sodium deoxycholate) extracts of MDA-MB-231 cells (Figure S3C, lanes 1, 4 and 5),
we believe that the interaction between ipomoeassin F and its target protein(s) may require a
particular subcellular environment that is detergent sensitive.

3.3(µM)
3.3(µM)
3.3(µM)

Figure 3. 3. Affinity pulldown using probe 3.3 with (A) or without (B) photo cleavage. Red
arrows indicate positive results; (C) Target validation by western blot with a Sec61α antibody.
Ipom-F, ipomoeassin F; AP, affinity pulldown.
We next investigated whether photocleavage is essential for the selective recovery of the two
putative target protein bands using probe 3.3. Strikingly, the ~40 kDa protein was also recovered
without photocleavage. It was substantially enriched by 3.3 when total streptavidin-bound products
were analyzed, and was lost in the presence of excess ipomoeassin F (Figure 3.3B, lanes 1–3). In
contrast, an enrichment of the ~100 kDa component under these conditions was not apparent
(Figures 3.3A and 3.3B).
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A.

B.

Figure 3. 4. Structure and cytotoxicity of ipomoeassin F analogues 3.4-3.5. (A) Structure of
probe 3.4 and 3.5; (B) Viability curve of 3.3, 3.4, 3.5 and ipomoeassin F in MDA-MB-231 and
MCF-7 (72h incubation).

To further investigate the factors that facilitate ~40 kDa protein recovery, we designed biotin
probe 3.4 (Figure 3.4) which contains -N- rather than -O- in the linker compared with probe 3.3
and its reduced analogue 3.5 (Figure 3.4) as reference compound. While substituting -N- with -Oin the linker triggers limited cytotoxicity disturbance, further reduction of the two α,β-unsaturated
double bonds leads to significant loss of the biological activity (Figure 3.4B). Then we performed
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biotin affinity pull down parallel with different probes and analyzed collected sample with SDSPAGE gel. Probe 3.4 (Figure 3.5, lane 4) specifically enriched ~40 kDa protein the same amount
of probe 3.3 (Figure 3.5, lane 2), inactive probe 3.5 (Figure 3.5, lane 3) exhibit no specific
enrichment as reference group.

Figure 3. 5. Affinity pulldown using probe 3.3, 3.4 and 3.5. Cells are treated with 20nM 1h
accordingly in each group.

Since photocleavage and subtle linker change were not essential for probe 3.3 to selectively
recover the 40 kDa protein, it is very likely that the increased linker length between the biotin
moiety and the ipomoeassin F region, but not its capacity for selective cleavage, significantly
improved the performance of probe 3.3 over probe 3.2. Another factor that plays critical role in
selectively isolating the 40 kDa protein is the exitance of double bound in cinnamate and tiglate
groups. The conclusion is supported by absence of the ~40 kDa protein recovery in 20nM
incubation after reducing the two double bonds (Figure 3.5, lane 2 and 3), even with 500 nM of
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3.5 affinity pull down (Figure S4B, lanes 1 and 4). Our data also suggest that, once formed, the
complex between probe 3.3 and the ~40 kDa protein is tight and can survive detergent mediated
cell lysis. This is further supported by pulldown of the ~40 kDa target protein with low
concentrations of probe 3.3 (10 nM) and ipomoeassin F (50 nM) (Figure S4A, lanes 1–3).
We next submitted both the ~40 kDa protein(s) (Figure 3.3B, lane 2) and the corresponding
regions of the gel for the negative control (Figure 3.3B, lane 1) and the ipomoeassin F competition
sample (Figure 3.3B, lane 3) for mass spectrometry analysis. When spectral counts were compared,
Sec61α (protein transport protein Sec61 subunit alpha isoform 1) stood out as the only protein that
was both substantially enriched in the pulldown with probe 3.3 and showed a corresponding
reduction when excess ipomoeassin F was present (Table S1). The selective recovery of Sec61α
by probe 3.3 was further confirmed by Western blotting (Figure 3C, cf. signals between input and
AP).
To further support Sec61α as a target protein responsible for the biological activity of
ipomoeassin F, we synthesized another reference compound 3.6 (Figure 3.6 and Table 3.1) by
removing both double bonds in cinnamate and tiglate. Inactive analogue 3.6 was ineffective at
competing with probe 3.3 binding, even when 3.6 was present in 50-fold excess (Figure S4B, cf.
lanes 1 to 3). Taken together, these findings further support the specificity of Sec61α as a primary
cellular target of ipomoeassin F.

Figure 3. 6. Structures of ipomoeassins F analogues 3.1 and 3.6.
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3.3.2. Cell Imaging Studies.
The Sec61 protein translocon plays an essential role in translocating newly synthesized
membrane and secretory polypeptides into and across the membrane of the endoplasmic reticulum
(ER).30,31 Sec61α forms the membrane conduit that nascent secretory polypeptides pass through.
To examine the subcellular localization of ipomoeassin F, we performed live cell imaging studies
using fluorescent analogue 3.7 (Figure 3.7) prepared from alkyne probe 3.1 using CuAAC. To
overcome the low fluorescent signal caused by internal photo-induced electron transfer and
photobleaching often encountered in fluorescent probe studies, rhodamine analogue 3.7 was
synthesized from the rhodamine azide precursor. Although 3.7 is between 5- and 40-fold less
potent than ipomoeassin F depending on the cell type analyzed, it retains substantial cytotoxicity
when compared to inactive analogues 3.5 and 3.6 (see Table 3.1), and we therefore used it for our
imaging studies.

Figure 3. 7. Structures of fluorescent derivative 3.7 of ipomoeassin F.

Subsequently, we confirmed that 3.7 could penetrate the cell membrane in a concentrationand time dependent manner and gave a strong fluorescent signal. Hence, 3.7 stained cells within
30 mins when present at 2 μM, but took >3 h to give clear images when used at 20 nM. When cells
labelled with 3.7 were co-stained with markers for either the ER or the nucleus, it was apparent
that 3.7 strongly labeled the ER (Figure 3.8), but not the nucleus (Figure S5A). To confirm the
specificity of ER labelling by 3.7, competition experiments were performed using ipomoeassin F
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or inactive compound 3.6. The fluorescence signal of 3.7 was almost completely abolished when
the cells were preincubated for 30 minutes with a 100-fold excess of free ipomoeassin F (Figure
S5B), yet preincubation with compound 3.6 had little effect (Figure S5C). The apparent ER
localization of the cellular interacting partner(s) of ipomoeassin F strongly supports the notion that
its target is Sec61α.

3.7

Figure 3. 8. Cell imaging studies with fluorescent probe 3.7 in MDA-MB-231 cells. Rhodamineconjugated ipomoeassin F analogue 3.7 (0.2 μM) was added to cells and after 1 hours, cells were
imaged to analyze localization of 3.7 relative to ER staining.
3.3.3. Pulldown from ER Microsomes.
As evidenced by the negative results from our pulldown experiments using cell lysates
prepared with detergent, we propose that the membrane environment of the ER may be required
to maintain Sec61α in a conformation that can bind to ipomoeassin F effectively. In this regard,
it would be unlikely that purified Sec61α alone could recapitulate a direct interaction with the
natural product. However, since the biological function of Sec61α is maintained in isolated ER
microsomes (provide by cooperation lab),32 and once pre-bound to probe 3.3 in intact cells the
resulting complex appears stable to detergent treatment (Figures 3.2A and 3.2B), we attempted to
pulldown Sec61α from purified ER-derived microsomes. After incubation with probe 3.3 and
detergent solubilization (10% n-dodecyl-ß-D-maltoside) to release biotin-bound proteins from the
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phospholipid bilayer, only a single protein was visible after pulldown (Figure S6A). The identity
of this product was confirmed as Sec61α by western blotting (Figure S6B). This finding strongly
supports our previous conclusion made with live cells, namely that Sec61α directly interacts with
ipomoeassin F.

3.3.4. Pulldown from ER Microsomes.
As evidenced by the negative results from our pulldown experiments using cell lysates
prepared with detergent, we propose that the membrane environment of the ER may be required
to maintain Sec61α in a conformation that can bind to ipomoeassin F effectively. In this regard,
it would be unlikely that purified Sec61α alone could recapitulate a direct interaction with the
natural product. However, since the biological function of Sec61α is maintained in isolated ER
microsomes,32 and once pre-bound to probe 3.3 in intact cells the resulting complex appears stable
to detergent treatment (Figures 3A and 3B), we attempted to pulldown Sec61α from purified ERderived microsomes. After incubation with probe 3.3 and detergent solubilization (10% n-dodecylß-D-maltoside) to release biotin-bound proteins from the phospholipid bilayer, only a single
protein was visible after pulldown (Figure S6A). The identity of this product was confirmed as
Sec61α by western blotting (Figure S6B). This finding strongly supports our previous conclusion
made with live cells, namely that Sec61α directly interacts with ipomoeassin F.

3.3.5. ipomoeassin F and Sec61α interaction mode exploration.
According to the information we got from biotin affinity pull down experiment, Sec61α can
form tight complex with probe 3.3 by direct interaction even at the concentration of 10nM in
membrane complete environment. The question that whether this complex sustained by a covalent
binding or strong non-covalent intermolecular interaction attracted our attention.
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Since IC50 of probe 3.3 against MDA-MB-231 is 7.0nM, we further narrowed down its work
concentration down to 5nM and found ~40 kDa protein enrichment still could be detectable (Figure
S4C, lane 1), suggesting the binding between probe 3.3 and Sec61α is very sensitive and strong.
Considering 5-fold of ipomoeassin F can easily keep the probe 3.3 out of binding site (Figure S4A)
and the single digital nanomolar cytotoxicity IC50 value against multiple cell lines, the connection
between ipomoeassin F and Sec61α seems to be a covalent binding.
Nevertheless, fluorescent streptavidin staining indicates that a stable covalent adduct
between the ~40 kDa protein and probe 3.3 was not formed under SDS-PAGE electrophoresis
(Figure S3B, lanes 4 and 5). The contradictory guided us to have a second thought on the
understanding about the binding mode between ipomoeassin F and target protein Sec61α.
Traditional competition is performed by the order of treating cells with probes (analogue 3.3)
followed by half an hour original compound (ipomoeassin F) management. The result from the
procedure would provide solid evidence that probe 3.3 and ipomoeassin F share the identical target,
however the result could not provide evidence to convince people about the binding mode. To
overcome this disadvantage, we switch the order of cell management. If the ipomoeassin F-protein
complex binding is covalent, ipomoeassin F would have little chance to squeeze the probe 3.3 out
binding pocket when treating cell after probe 3.3 management. Vice versa, If the secondary
treatment of ipomoeassin F can peel its probe 3.3 off after the probe-protein complex fully
generated, it is more likely that binding is non-covalent.
We gradually increase the reverse 100-fold competition intensity in the order of: ipomoeassin
F 0.5h treatment followed by 1h probe 3.3 management (Figure 3.9A, lane 4), ipomoeassin F 1h
treatment followed by 1h probe 3.3 management (Figure 3.9B, lane 4). Short time reverse
competition competes away very limited protein binding compared with traditional pulldown
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experiment (Figure 3.9A, lane 2). But with the elongation of competition time, more and more
probe-protein complex become dissociated (Figure 3.9B, lane 4). The increase of competition
effectiveness in the reverse treatment supports the idea that ipomoeassin F targets Sec61α most
likely by strong non-covalent binding or through reversible weak covalent binding.
A.

B.

Figure 3. 9. traditional completion and reverse competition between ipomoeassin F and analogue
3.3: (A) ipomoeassin F 0.5h competition after 1h 3.3 incubation; (B) ipomoeassin F 1h competition
after 1h 3.3 incubation.
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3.4.Conclusions
Here, we report comprehensive chemical biology studies of ipomoeassin F to understand the
molecular basis for its potent cytotoxicity. By designing and evolving our chemical probes on an
empirical basis, Sec61α was ultimately identified and validated as a direct and physiologically
relevant target of ipomoeassin F. The absence of fluorescent streptavidin staining we observed
indicates ipomoeassin F is unlikely to form a stable covalent complex with Sec61α, despite the
presence of two Michael acceptor systems in its structure (cinnamate and tiglate, Figure 3.1).
Moreover, reverse competition supports the non-covalent binding between ipomoeassin F and
Sec61α. We therefore conclude that the pulldown of Sec61α with probe 3.3 represents a successful
biotin affinity enrichment of a non-covalent ligand-membrane protein complex formed in live cells,
most likely reflecting a slow disassociation rate of ipomoeassin F from Sec61α. The binding of
ipomoeassin F to cellular Sec61α is supported by the ER staining seen with a fluorescent version
of the compound, the highly selective pulldown of Sec61α from ER-derived microsomes and the
ability of ipomoeassin F to compete with cotransin for Sec61α binding.
In short, we provide compelling evidence that the core α subunit of the Sec61 translocation
complex is the major target for ipomoeassin F in a cellular context, thereby opening the way for
the exploitation of ipomoeassin F for target-based drug discovery. More broadly, given its
comparatively advantageous synthesis, we anticipate that ipomoeassin F and its analogues/probes
will provide accessible new molecular tools that will help our efforts to fully define the molecular
basis for Sec61-mediated protein translocation at the ER membrane.
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3.5.Supporting Information
3.5.1. Cytotoxicity Assay
3.5.1.1. Cell Culture
Two human breast cancer cell lines (MDA-MB-231 and MCF7) and one human breast
nontumorigenic epithelial cell line (MCF-10A) were maintained in a DMEM high glucose culture
medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. The cells were
grown in a humidified atmosphere of 5% CO2 and 95% air at 37 ºC. The culture medium was
changed every 2–4 days depending on cell density. Cell cultures were passaged once a week using
0.125% trypsin-EDTA to detach the cells from culture flasks/dishes.
3.5.1.2. MTT Cytotoxicity Assay
Viable cells were counted with a hemocytometer immediately before each experiment.
Experiments were done in triplicate. First, 100 μL of MCF7 cells at the density of 50,000 cells/mL
were seeded in a 96-well plate (5,000 cells/well), which was incubated at 37 ºC and 5% CO2
atmosphere for 24 h. The compounds were dissolved in DMSO (dimethyl sulfoxide) to make drug
stocks (10 mM). The stock solutions were diluted with the complete DMEM high glucose culture
medium to make a series of gradient fresh working solutions right before each test. Subsequently,
the cells were treated with 100 μL of the freshly made gradient working solution in the total volume
of 200 μL/well for 72 h. After that, the media were discarded and 200 μL of the fresh complete
medium containing 10% of MTT stock solution (5 mg/mL) was added to each well. The plate was
then incubated at 37 ºC and 5% CO2 for 3 h. Next, 180 μL of the medium was discarded from each
well, and 180 μL of DMSO was added to each well to dissolve formazan crystals. Absorbance of
formazan was detected by a microplate reader (BioTek Synergy H1) at 570 nm with 650 nm as the
reference wavelength. The percentage of viability compared to the negative control (DMSO55

treated cells) was determined. GraphPad Prism 6 software was used to make a plot of %
viability versus sample concentration and to calculate the concentration at which a compound
exhibited 50% cytotoxicity (IC50).
3.5.1.3. AlamarBlue Cytotoxicity Assay
MDA-MB-231 and MCF-10A Viable cells were counted with a hemocytometer
immediately before each experiment. Experiments were done in triplicate. First, 100 μL of MDAMB-231 cells or MCF10A cells at the density of 50,000 cells/mL was seeded in a 96-well plate
(5,000 cells/well) and then incubated at 37 ºC and 5% CO2 for 24 h. The compounds were dissolved
in DMSO (dimethyl sulfoxide) to make drug stocks (10 mM). The stock solutions were diluted
with the complete DMEM high glucose culture medium to make a series of gradient fresh working
solutions right before each test. Subsequently, the cells were treated with 100 μL of the freshly
made gradient working solution in the total volume of 200 μL/well for 72 h. After that, the media
were discarded and 200 μL of the fresh complete medium containing 10% of AlamarBlue
(resazurin) stock solution (3 mg/27.15mL) (5 mg/mL) was added to each well. The plate was then
incubated at 37 ºC and 5% CO2 for another 3 h. Emission of each well at 620 nm was detected by
a microplate reader (BioTek Synergy H1) at excitation 580 nm. The percentage of viability
compared to the negative control (DMSO-treated cells) was determined. GraphPad Prism 6
software was used to make a plot of % viability versus sample concentration and to calculate the
concentration at which a compound exhibited 50% cytotoxicity (IC50).

3.5.2. Stepwise Activity Based Protein Profiling
MDA-MB-231 cells were seeded in five groups of 6 cm petri dishes with 3 ml DMEM high
glucose culture and incubated at 37 ºC and 5% CO2 until 90% confluency. Each group was treated
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with fresh medium containing 20 µM competitor or an equal volume of DMSO vehicle for 30 min
at 37 ºC and 5% CO2, followed by addition of 0.2 µM probe or an equal volume of DMSO. After
1 h incubation at 37 ºC and 5% CO2, the cells were harvested and washed with cold PBS for 3
times. The cells were then lysed in 100 µl of lysis buffer 1 (50 mM Hepes pH = 9.0, 100 mM NaCl,
10% glycerol, 5 mM MgCl2, 1 mM CaCl2, 0.2% NP40, 1x protease inhibitor) using ultrasound
sonication. The supernatant of each group was collected after centrifugation at 21,100 g and 4 ºC
for 10 min, and the protein concentration was quantified with a BCA kit. 10% SDS was then added
into protein solution to make a final SDS concentration of 0.4%, and the solution was incubated at
95 ºC for 5 min. 1 µl TECP (100 mM stock solution in H2O) was mixed with 1 µl TBTA (10 mM
stock solution in a 4:1 ratio of t-butanol and DMSO), 1 µl CuSO4 (100 mM stock solution in H2O),
and 1 µl rhodamine-azide (1 mM stock solution in DMSO). The mixed solution was added into
the previously prepared protein solution containing 0.25 mg protein. The total volume was adjusted
to 100 µl with the lysis buffer 1 to make a final protein concentration of 2.5 mg/ml, and the click
reaction was performed at room temperature for 1.5 h. Proteins in 15 µl of the reactant were
fractionated by an SDS-PAGE gel. The protein gel was scanned with a typhoon scanner
(Typhoon™ FLA 9500) at 532 nm excitation with 700 mV gain setting and then stained with
Coomassie blue.

3.5.3. Biotin Affinity Pulldown
3.5.3.1. Live Cell-based Pulldown
According to the experimental needs, MDA-MB-231 cells were seeded into 3-7 groups of
15-cm tissueculture dishes and incubated at 37 ºC and 5% CO2 until 90% confluency. Each group
was treated with fresh medium containing a competitor or an equal volume of DMSO vehicle for
30 min at 37 ºC and 5% CO2, followed by addition of a probe or an equal volume of DMSO. After
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1 h incubation at 37 ºC and 5% CO2, the cells were harvested and washed with cold PBS for 3
times and lysed with the lysis buffer 2 (50 mM Tris pH=7.4, 150 mM NaCl, 1% NP40, 0.25%
sodium deoxycholate, 10 mM NaF, 10 mM β-glycerophosphate, and 1 mM Na3VO4). The
supernatant of each group was collected after centrifugation at 4 ºC and 21,100 g for 10 min, and
the protein concentration was quantified with the BCA kit. After adjusting protein concentration
with lysis buffer 2, each protein solution with equal amount of total protein in the same volume
was incubated with 20 µl of washed streptavidin bead at 4 ºC for 2 h with rotation. After incubation,
the beads were washed with washing buffer (50 mM Tris pH=7.4, 150mM NaCl, 1% NP40, 0.25%
Sodium deoxycholate, 10 mM NaF, 10 mM β-glycerophosphate, and 1 mM Na3VO4) for 3
times and boiled at 95ºC for 5 min in 2x sample buffer (125 mM Tris-HCl PH=6.8, 20% Glycerol,
2% SDS, 2% β-mercaptoethanol and 0.02% Bromophenol blue). After centrifugation at 21,100 g
and 4 ºC for 1 min, the cleared eluted proteins were divided into two parts. One part was
fractionated by a 12% SDS PAGE and visualized by silver staining. The other part was analyzed
by Western blotting, in which proteins on the nitrocellulose membrane were visualized by either
fluorescently labeled streptavidin or an anti-Sec61α antibody.
3.5.3.2. Cell Lysate-based Pulldown
MDA-MB-231 cells from seven 15-cm tissue culture dishes were harvested and washed with
PBS for 3 times and lysed in buffer 2 using ultrasound sonication. The supernatant of each group
was collected after centrifugation at 21,100 g and 4 ºC for 10 min, and the protein concentration
was quantified with the BCA kit and adjusted to be between 3.5–4 mg/mL with lysis buffer 2.
Next, the cell lysate was equally divided into 7 fractions, 1 ml/each. Each fraction was treated with
either a competitor or an equal volume of DMSO vehicle for 30 min at 4 ºC, followed by the
addition of a probe or an equal volume of DMSO. All the samples were then incubated at 4 ºC for
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1 h. After incubation, 20 µl of streptavidin washed bead was added to each sample followed by 2
h incubation at 4 ºC with rotation. The remaining procedures were the same as the live cell-based
pulldown (see above).
3.5.3.3. ER Microsome-based Pulldown
1 ul of Ipomoeassin F (2 mM stock concentration) or DMSO vehicle was added to 198.6 ul
ER microsome suspension in one of the three Eppendorf tubes to produce a final ipomoeassin F
concentration of 10 µM and two blank tubes. The resulting mixtures were incubated at 4 ºC for 30
min, followed by addition of 0.2 µM probe (final concentration) to two tubes or an equal volume
of DMSO to a blank tube. After 1 h incubation at 4 ºC, 10% DDM (n-dodecyl-ß-D-maltoside) was
added to each tube to give the final concentration of 1%, and the mixtures were further incubated
at 4 ºC for another 1 h. The supernatant of each group was collected after centrifugation at 4 ºC
and 21,100 g for 10 min. 20 µl of washed streptavidin beads was added to each sample followed
by 2 h incubation at 4 ºC with rotation. After washing with washing buffer (50 mM Tris pH=7.4,
and 150 mM NaCl) for 3 times, the bound proteins were eluted by were boiling the beads in 20 µl
of 2x sample buffer at 95 ºC for 5 min. The eluted proteins were analyzed by SDS-PAGE or
Western blotting as described above.

3.5.4. Mass Spectrometry (MS) Analysis and MS Data Processing
In the pulldown, the bound proteins were eluted via boiling the high capacity streptavidin
agarose beads in 1x sample buffer. The eluted proteins were fractionated with a 12% SDS-PAGE
and the fractionated proteins were visualized by blue silver staining.33 The 40 kDa protein band
from the probe 3.3-enriched sample and the corresponding regions of the gel for the negative
control and the ipomoeassin F competition sample were cut, in-gel digested, the resulting peptides
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were analyzed by an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific), and the
MS/MS spectra were searched against a composite target-decoy UniProtkB human protein
database (2018_02, 20317 entries) using Mascot (Matrix Science, London, UK; version 2.5.1) as
described previously.

34-35

The parameters for database searching were as follows: MS tolerance

of 3.0 ppm and MS/MS tolerance of 0.5 Da; tryptic enzyme specificity with a maximum of 2
missed cleavages; fixed modification, carbamidomethyl of cysteine; and variable modifications,
oxidation of methionine and acetylation of the N-terminus. Search results were further processed
by Scaffold software (version 4.8.6; Proteome Software, Portland, OR) for viewing protein and
peptide identification information. In the Scaffold analysis, peptide identifications were accepted
if they could achieve a false discovery rate (FDR) of <1.0% by the Scaffold Local FDR algorithm.
Protein identifications were accepted if they could achieve an FDR of <1.0% and contained at least
2 identified peptides. Total spectral counts were exported from Scaffold and used to represent
relative protein abundance from different samples based on the positive, linear correlation between
spectral count and the abundance of a protein in complex samples.36-38 Contaminant proteins such
as keratins were discarded. For reliable representation of protein abundance, proteins identified
with <4 spectra in the probe 3.3 - enriched sample were discarded.37
3.5.5. Cell Imaging
MDA-MB-231 cells were seeded on fibronectin-coated coverslips at 70% confluency in a
48-well plate and cultured at 37 ºC and 5% CO2. After 24 h, culture medium was replaced with
fresh medium containing a 20 µM competitor or an equal volume of DMSO vehicle for 30 min at
37 ºC and 5% CO2, followed by addition of 0.2 µM (final concentration) fluorescent probe 3.7.
After 1 h incubation, the coverslips were mounted onto a glass slide with a mounting medium with
or without 0.5 µg/ml DAPI. The fluorescent images were acquired with a confocal microscope
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(Leica TCS SP5) using 405 nm excitation and 562 nm excitation. For the ER co-localization
studies, 1uM ER-Tracker™ Blue-White DPX was added to the medium after 1 h incubation with
probe 3.7. After 5 min incubation, the coverslips were mounted onto a glass slide and the images
were acquired as described above.
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3.5.6. Figures and Tables
3.5.6.1. Cell Cytotoxicity Assay

Figure S 1. Cytotoxicity in MDA-MB-231: Cell viability curves of analogues 3.1, 3.2, 3.3, 3.7
and ipomoeassin F (72 h incubation).
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3.5.6.2. Stepwise Activity Based Protein Profiling
A.

B.

Figure S 2. Click reaction performed after incubating cells with competitor and its corresponding
alkyne probe. (A) Fluorescent image by a Typhoon scanner. (B) Coomassie Blue stain of the gel.
(The arrow indicates a positive result for probe X, where a protein band appeared in lane 4 but was
absent in lanes 1 and 5.)
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3.5.6.3. Biotin Affinity Pulldown
A.

B.

C.

Figure S 3. Biotin affinity pulldown with probes 3.2 and 3.3. Cells were incubated with
ipomoeassin F and probes, then lysed and subjected to biotin affinity pulldown with streptavidin
beads. (A) SDS-PAGE and silver staining analysis of pulldown samples from live cells. (B) SDSPAGE analysis of pulldown samples from live cells using fluorescently labeled streptavidin. (C)
SDS-PAGE and silver staining analysis of pulldown samples from cell lysates. Arrows indicate
the ~40 kDa position.
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A.

B.

C.

Figure S 4. Biotin affinity pulldown with probe 3.3 or 3.5 in the presence of the competitor
ipomoeassin F or 3.6. (A) Pulldown experiment with 10 nM 3.3 and 50 nM ipomoeassin F. (B)
Pulldown experiments with either 20 nM 3.3 and 1 μM 3.6 or 500 nM 3.5 without competition.
Arrows indicate the ~40 kDa position. (C) Pulldown experiment with 5nM and 10nM 3.3.
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3.5.6.4. Cell Imaging
A.

3.7, 0.2µM

DAPI

Merged

3.7 (0.2 μM) + Ipom-F (20 μM)

DAPI

Merged

DAPI

Merged

B．

C．

3.7 (0.2 μM) + 3.6 (20 μM)

Figure S 5. Live cell imaging-based competition experiments. (A) Cells were treated with 1 μM
3.7. (B) Cells were treated with ipomoeassin F (100-fold) and 3.7; (C) Cells were treated with 3.6
(100-fold) and 3.7.
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3.5.6.5. Pulldown in ER Microsomes.
A.

B.

Ipomoeassin F
3.3

Sec61α

Figure S 6. Biotin affinity pulldown with probe 3.3 in ER microsomes. (A) The proteins were
visualized by silver staining. The arrow indicates the positive result. (B) The proteins were
transferred onto a nitrocellulose membrane and visualized by western blot using an anti-Sec61α
antibody.
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Table S 1.
Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Vimentin

VIME_HUMAN

Protein transport
protein
Sec61 subunit
alpha
isoform 1

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

54 kDa

108

88

126

0.7

S61A1_HUMAN

52 kDa

11

80

16

5

Pyruvate
carboxylase,
mitochondrial

PYC_HUMAN

130 kDa

97

68

109

0.62

Poly(rC)-binding
protein
1

PCBP1_HUMAN

37 kDa

45

45

82

0.55

mRNA export
factor

RAE1L_HUMA
N

41 kDa

50

41

53

0.77

Actin,
cytoplasmic 1

ACTB_HUMAN

42 kDa

45

40

54

0.74

Stomatin-like
protein 2,
mitochondrial

STML2_HUMA
N

39 kDa

42

37

68

0.54

Enoyl-CoA delta
isomerase 2,
mitochondrial

ECI2_HUMAN

44 kDa

34

36

51

0.71

68

Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Plectin

PLEC_HUMAN

MethylcrotonoylCoA
carboxylase
subunit
alpha,
mitochondrial

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

532 kDa

30

29

65

0.45

MCCA_HUMAN

80 kDa

42

28

44

0.64

26S proteasome
regulatory subunit
10B

PRS10_HUMAN

44 kDa

27

25

45

0.56

Acetyl-CoA
acetyltransferase,
mitochondrial

THIL_HUMAN

45 kDa

24

25

37

0.68

Core histone
macro
H2A.1

H2AY_HUMAN

40 kDa

30

24

50

0.48

Heterogeneous
nuclear
ribonucleoprotein
A3

ROA3_HUMAN

40 kDa

35

24

47

0.51

69

Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

MethylcrotonoylCoA
carboxylase beta
chain,
mitochondrial

MCCB_HUMAN

DnaJ homolog
subfamily
B member 11

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

61 kDa

36

23

37

0.62

DJB11_HUMAN

41 kDa

25

21

28

0.75

Fructosebisphosphate
aldolase A

ALDOA_HUMA
N

39 kDa

55

21

37

0.57

Succinate--CoA
ligase
[GDP-forming]
subunit
beta,
mitochondrial

SUCB2_HUMA
N

47 kDa

25

21

28

0.75

Poly(rC)-binding
protein
2

PCBP2_HUMAN

39 kDa

23

20

34

0.59
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Cytosolic acyl
coenzyme
A thioester
hydrolase

BACH_HUMAN

Transmembrane
protein
43

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

42 kDa

23

19

23

0.83

TMM43_HUMA
N

45 kDa

19

18

21

0.86

HLA class I
histocompatibility
antigen, A-2
alpha chain

1A02_HUMAN

41 kDa

8

8

16

0.5

Mevalonate
kinase

KIME_HUMAN

42 kDa

10

8

15

0.53

Mitotic
checkpoint
protein BUB3

BUB3_HUMAN

37 kDa

8

8

15

0.53

Nucleolar protein
7

NOL7_HUMAN

29 kDa

9

8

10

0.8

Nucleolysin
TIAR

TIAR_HUMAN

42 kDa

9

8

13

0.62
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Protein KTI12
homolog

KTI12_HUMAN

Protein SGT1
homolog

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

39 kDa

4

8

12

0.67

SGT1_HUMAN

41 kDa

8

8

22

0.36

Transcriptional
activator
protein Pur-alpha

PURA_HUMAN

35 kDa

15

8

19

0.42

Tropomodulin-3

TMOD3_HUMA
N

40 kDa

15

8

19

0.42

40S ribosomal
protein
SA

RSSA_HUMAN

33 kDa

7

7

13

0.54

Cytoskeletonassociated
protein 4

CKAP4_HUMA
N

66 kDa

5

7

12

0.58

Erlin-1

ERLN1_HUMA
N

39 kDa

8

7

9

0.78

Mitochondrial
inner
membrane protein
OXA1L

OXA1L_HUMA
N

49 kDa

8

7

9

0.78
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Polymerase delta
interacting
protein 3

PDIP3_HUMAN

Rab11 familyinteracting
protein 5

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

46 kDa

8

7

11

0.64

RFIP5_HUMAN

70 kDa

7

7

10

0.7

T-complex
protein 1
subunit delta

TCPD_HUMAN

58 kDa

14

7

13

0.54

tRNA
methyltransferase
10 homolog C

TM10C_HUMA
N

47 kDa

13

7

14

0.5

Ubiquitin-60S
ribosomal
protein L40

RL40_HUMAN

15 kDa

7

7

12

0.58

V-type proton
ATPase
subunit C 1

VATC1_HUMA
N

44 kDa

10

7

15

0.47
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

28S ribosomal
protein
S5, mitochondrial

RT05_HUMAN

Activitydependent
neuroprotector
homeobox protein

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

48 kDa

7

6

15

0.4

ADNP_HUMAN

124 kDa

6

6

9

0.67

Aspartate
aminotransferase,
cytoplasmic

AATC_HUMAN

46 kDa

21

6

16

0.38

COP9
signalosome
complex subunit
4

CSN4_HUMAN

46 kDa

7

6

9

0.67

Eukaryotic
translation
initiation factor 3
subunit
H

EIF3H_HUMAN

40 kDa

6

6

17

0.35
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Ferrochelatase,
mitochondrial

HEMH_HUMAN

Filamin-B

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

48 kDa

9

6

13

0.46

FLNB_HUMAN

278 kDa

8

6

10

0.6

Glutaminylpeptide
cyclotransferaselike
protein

QPCTL_HUMA
N

43 kDa

7

6

6

1

Heat shock
protein HSP
90-beta

HS90B_HUMAN

83 kDa

14

6

15

0.4

Hemoglobin
subunit
alpha

HBA_HUMAN

15 kDa

10

6

2

3

Mannose-1phosphate
guanyltransferase
beta

GMPPB_HUMA
N

40 kDa

6

6

13

0.46

Nucleolin

NUCL_HUMAN

77 kDa

5

6

6

1
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Proline-rich
protein 11

PRR11_HUMAN

Protein arginine
N
methyltransferase
1

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

40 kDa

11

6

14

0.43

ANM1_HUMAN

42 kDa

11

6

14

0.43

Short/branched
chain
specific acyl-CoA
dehydrogenase,
mitochondrial

ACDSB_HUMA
N

47 kDa

4

6

11

0.55

SUMO-activating
enzyme subunit 1

SAE1_HUMAN

38 kDa

11

6

12

0.5

Ubiquitinconjugating
enzyme E2 Z

UBE2Z_HUMA
N

38 kDa

8

6

10

0.6

Alpha-actinin-1

ACTN1_HUMA
N

103 kDa

3

5

8

0.63
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Alpha-actinin-4

ACTN4_HUMA
N

Cholinephosphate
cytidylyltransfera
se A

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

105 kDa

11

5

11

0.45

PCY1A_HUMA
N

42 kDa

2

5

5

1

DnaJ homolog
subfamily
B member 2

DNJB2_HUMAN

36 kDa

5

5

3

1.67

Fructosebisphosphate
aldolase C

ALDOC_HUMA
N

39 kDa

21

5

13

0.38

GDP-mannose
4,6
dehydratase

GMDS_HUMAN

42 kDa

9

5

11

0.45

Heat shock
cognate 71
kDa protein

HSP7C_HUMAN

71 kDa

14

5

19

0.26

Hsp70-binding
protein 1

HPBP1_HUMAN

39 kDa

6

5

8

0.63
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Matrin-3

MATR3_HUMA
N

Minor
histocompatibility
antigen H13

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

95 kDa

2

5

7

0.71

HM13_HUMAN

41 kDa

6

5

7

0.71

Nucleoside
diphosphate
kinase 7

NDK7_HUMAN

42 kDa

9

5

10

0.5

Probable ATPdependent
RNA helicase
DDX5

DDX5_HUMAN

69 kDa

6

5

11

0.45

Probable
methyltransferase
-like
protein 15

MET15_HUMA
N

46 kDa

5

5

10

0.5
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Propionyl-CoA
carboxylase alpha
chain,
mitochondrial

PCCA_HUMAN

Propionyl-CoA
carboxylase beta
chain,
mitochondrial

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

80 kDa

11

5

13

0.38

PCCB_HUMAN

58 kDa

7

5

6

0.83

Replication factor
C
subunit 2

RFC2_HUMAN

39 kDa

4

5

25

0.2

RNA 3'-terminal
phosphate cyclase

RTCA_HUMAN

39 kDa

6

5

9

0.56

Serine/threonineprotein
kinase MARK2

MARK2_HUMA
N

88 kDa

3

5

4

1.25

Serpin B9

SPB9_HUMAN

42 kDa

11

5

9

0.56

Twinfilin-2

TWF2_HUMAN

40 kDa

10

5

10

0.5
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

7dehydrocholester
ol
reductase

DHCR7_HUMA
N

Alpha-2macroglobulin
receptorassociated
protein

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

54 kDa

3

4

2

2

AMRP_HUMAN

41 kDa

2

4

4

1

Apoptosisinducing
factor 2

AIFM2_HUMAN

41 kDa

5

4

13

0.31

ATPase ASNA1

ASNA_HUMAN

39 kDa

3

4

5

0.8

BRISC and
BRCA1-A
complex member
1

BABA1_HUMA
N

37 kDa

6

4

11

0.36

cAMP-dependent
protein
kinase catalytic
subunit
alpha

KAPCA_HUMA
N

41 kDa

16

4

13

0.31
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Cdc42 effector
protein 1

BORG5_HUMA
N

Desmocollin-1

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

40 kDa

6

4

9

0.44

DSC1_HUMAN

100 kDa

0

4

0

#DIV/0!

Filamin-A

FLNA_HUMAN

281 kDa

7

4

8

0.5

Flap
endonuclease 1

FEN1_HUMAN

43 kDa

3

4

7

0.57

Glucose-fructose
oxidoreductase
domain
containing protein
1

GFOD1_HUMA
N

43 kDa

4

4

5

0.8

HAUS augminlike
complex subunit
4

HAUS4_HUMA
N

42 kDa

1

4

11

0.36

Heat shock 70
kDa
protein 1A

HS71A_HUMAN
(+1)

70 kDa

6

4

7

0.57
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

HLA class I
histocompatibility
antigen, alpha
chain E

HLAE_HUMAN

HLA class I
histocompatibility
antigen, B-41
alpha
chain

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

40 kDa

5

4

4

1

1B41_HUMAN

41 kDa

2

4

4

1

Isovaleryl-CoA
dehydrogenase,
mitochondrial

IVD_HUMAN

46 kDa

8

4

8

0.5

MAP7 domain
containing protein
3

MA7D3_HUMA
N

98 kDa

4

4

8

0.5

Monocarboxylate
transporter 4

MOT4_HUMAN

49 kDa

4

4

7

0.57

Muscleblind-like
protein
1

MBNL1_HUMA
N

42 kDa

3

4

5

0.8

Pinin

PININ_HUMAN

82 kDa

2

4

5

0.8

Polyhomeoticlike
protein 2

PHC2_HUMAN

91 kDa

4

4

4

1

RelA-associated
inhibitor

IASPP_HUMAN

89 kDa

1

4

7

0.57

Serum albumin

ALBU_HUMAN

69 kDa

4

4

4

1
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Spectral Counts for Proteins Identified in ~40 kDa Bands from LC/MS
Spectral count
Identified
Proteins

Accession
Number

Molecular
Weight

Stress-70 protein,
mitochondrial

GRP75_HUMAN

Synaptic vesicle
membrane protein
VAT1 homolog

7+
delta
Ipom (Probe/probe
F
+ Ipom-F)

DMSO

Probe
7

74 kDa

5

4

6

0.67

VAT1_HUMAN

42 kDa

3

4

10

0.4

Testis-expressed
protein
264

TX264_HUMAN

34 kDa

7

4

10

0.4

Transcription
factor jun
B

JUNB_HUMAN

36 kDa

4

4

9

0.44

Transformer-2
protein
homolog beta

TRA2B_HUMA
N

34 kDa

5

4

6

0.67

UBX domaincontaining
protein 1

UBXN1_HUMA
N

33 kDa

4

4

5

0.8
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CHAPTER 4. FUTURE PROJECT: APPLICATION FOR HIGH-THROUGHPUT
SCREENING

As early as 1990s, high-throughput screening (HTS) of synthetic chemistry libraries against
various potential therapeutic targets has been applied into pharmaceutic industry.1 For recent
decades, a significant number of natural products were isolated and characterized with the help of
bioactivity screening.2 Nowadays, HTS is considered as one of the most key tools in drug
discovery within the pharmaceutical industry. With the employment of HTS, tens of thousands of
compounds can be tested in a week to identify the specific mechanisms of different compounds.3
However, there is still a large numbers of potential interesting compounds that may be missed
due the limit detecting sensitivity and screening throughput efficacy. With the application of new
techniques and advances in data management, screening sensitivity has greatly improved. Mass
spectrometry (MS)-based metabolomic profiling is one of those newly developed method. Even
though this technique is acknowledged as a very sensitive screening approach, it is not easy to
have it well established in practical throughput screening. Therefore, people are continuously
looking for high-throughput strategies with ‘low-tech’ but robust output.
Sec61, a complex consisted of subunit α, β and γ, constitutes a heterotrimer.4 Multiple
heterotrimers cluster together to build up a transmembrane aqueous pore channel,5-7 which enables
of newly synthesized secretory proteins translocation and helps with membrane protein integration
as well.4,8 As discussed in Chapter 3, ipomoeassin F specifically binds Sec61α leading to its single
digital nanomolar cytotoxicity IC50 value. This non-covalent binding or reversible covalent weak
binding between ipomoeassin F probes and Sec61α can be outcompeted by adequate amounts of
ipomoeasin F since they bind the same target protein. In future project, I will be trying to make the
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competition easily monitorable with relatively small amounts of material and time, so that it could
be used as a potential high throughput screening for Sec61α binding compound.
4.1.Fluorescent probe based HTS study
Fluorescent probes have been frequently used for exploring many kinds of bio-activities by
taking advantage of their indispensable sensitivity and easily accessibility. They could be easily
traceable at very low quantity, sensitive to ionic strength, PH, viscosity, temperature and
hydrophobicity.9 Moreover, the fluorescent probes can even present subcellular constitution by
specific binding to regional specific molecules like DNA, proteins or lipids within organelles.

4.1.1. Mechanism for fluorescent probe based HTS research
Probe 4.1(Figure 4.1) was shown to be an active compound with strong emission signal when
achieved with the proper excitation wavelength and to maintain favorable stability under
reasonable continuous excitation.

Figure 4. 1. Ipomoeassin F analogues 4.1, 4.2.
The fluorescent intensity variation reflects probe - target protein complex binding and
dissociation dynamics. As a result, ipomoeassin F that possesses strong potency and same target
would perfectly compete probe 4.1 off the target protein binding site, therefore lessens the
detectable fluorescent intensity (Figure 4.2B); while inactive analogue 4.2 that has no common
binding site could not push 4.1 out of the protein binding pocket therefore causes no signal
disturbance (Figure 4.2C). If the same competition was performed on an unknown compound,
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detectable numerical fluorescent intensity would be a convenient and accurate indicator for
whether this test compound harbors Sec61α affinity.
A．

4.1, 0.2µM

B.

4.1 (0.2µM) + Ipom-F (20 µM)

C.

4.1 (0.2µM) + 4.2 (20 µM)

Figure 4. 2. Live cell imaging-based competition experiments. (A) Cells were treated with 0.2 μM
4.1. (B) Cells were treated with 20 μM ipomoeassin F and 0.2 μM 4.1; (C) Cells were treated with
20 μM 4.2 and 0.2 μM 4.1.
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Due to the complicated synthesis of homemade positive control ipomoeassin F and negative
control 4.2, minimizing their required amount during the screening is critical to the feasibility as a
potential HTS approach. Since HTS may be performed on tens of thousands of compounds,
optimized time for the whole process is another critical factor that adds weigh to its potential
availability for realistic application. In this project, I use probe 4.1 fluorescent signal intensity as
an indicator, and ipomoeassin F and probe 4.2 are recruited as positive control and negative control
respectively. The goal is to figure out the optimized efficacy on breast cancer cell line MDA-MB231 so that it could be possibly used as an HTS for compounds that target Sec61α.

4.1.2. Optimal work concentration exploration for cell imaging
Work concentration of probe 4.1 is directly related to the corresponding competition controls,
so the minimum amount for relative acceptable clear image is an ideal expected work concentration.
Since the IC50 value of 4.1 is 253.4nM against MDA-MB-231, 500nM was set to be the highest
testing concentration.
A.
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B.

C．

D.
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E．

Figure 4. 3. Live cell imaging from 4.1 incubation at different concentration. (A) Cells were
treated with 25nM 4.1; (B) Cells were treated with 50nM 4.1; (C) Cells were treated with 100nM
4.1; (D) Cells were treated with 200nM 4.1; (E) Cells were treated with 500nM 4.1.
According to the image collected (Figure 4.3), when cells are treated with concentration
below 100nM, cell image become clearer as we increase the work concentration; as the work
concentration increased above 100nM, cell morphology is well detected, and signal intensity
increase at very limited amount. As a result, 100nM is selected to be the best work concentration.

4.1.3. Optimal treatment time exploration for cell imaging
As a potential HTS test, consumption of positive control ipomoeassin F and negative control
4.2 is one of the biggest concerns, but time cost is also a critical unignorable factor. In order to
push up the efficiency for competition test, we tried a serious of time to treat cells with probe 4.1
at work concentration 100nM.
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A.

B.

C.
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D.

E.

F.

94

G.

Figure 4. 4. Live cell imaging from 4.1 100nM treatment at different time incubation: (A) Cells
were incubated for 5min; (B) Cells were incubated for 15min; (C) Cells were incubated for 30min;
(D) Cells were incubated for 45min; (E) Cells were incubated for 60min; (F) Cells were incubated
for 2h; (G) Cells were incubated for 8h.

Without doubt, as the treatment time of 4.1 elongated, cell morphology is becoming more
and more discernable (Figure 4.4). When the time goes beyond 1h, fluorescent intensity become
stable even given 8h incubation. Therefore, 1h is optimized time when 4.1 labelling and
disassociation become balanced.

4.1.4. Optimal fold competition of ipomoeassin F for cell imaging
Since the optimized work concentration for probe 4.1 is fixed at 100nM 1h, the best condition
for competition become the next question. To better understand workable competition condition,
we tried the competition between ipomoeassin F and probe 4.1 at the fold change ranging from
25-fold to 100-fold.
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A.

B.

C.
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D.

Figure 4. 5. Live cell confocal fluorescent microscopy imaging from 1h 4.1 0.1 μM treatment and
30min ipomoeassin F competition at different competition fold difference: (A) Cells were treated
with 4.1 without competition; (B) Cells were treated with 4.1 with 25-fold ipomoeassin F
competition; (C) Cells were treated with 4.1 with 50 fold ipomoeassin F competition; (D) Cells
were treated with 4.1 with 100 fold ipomoeassin F competition.

As expected (Figure 4.5), little competitive effect could be detected at 25 and 50-fold
ipomoeassin F competition. However, when the concentration of ipomoeassin F increased to 100fold competition, fluorescent signal was almost competed off. As a result, 100-fold competition is
figured out to be the ideal condition for the potential HTS.

4.1.5. Optimal competition time of ipomoeassin F for cell imaging
As discussed above, 100-fold of ipomoeassin F completion almost removes fluorescent
signal form probe 4.1 (Figure 4.5D), but the best competition time is unknown. Since the passive
penetration of small molecular is very fast, the competition time increases gradually by every 5min,
until the competition will not improve with passage of time.

97

A.

B.

C.
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D.

Figure 4. 6. Live cell imaging from 1h 4.1 0.1 μM treatment and 100-fold ipomoeassin F
competition at different competition time: (A) Cells were treated with 4.1 without competition; (B)
Cells were treated with 5 min competition; (C) Cells were treated with 10 min competition; (D)
Cells were treated with 15 min competition.

Probe 4.1 The fluorescent signal perishes fast within 10min competition and keeps a certain
level ever since then. Compared with 1h incubation to reach peak binding for probe 4.1 at 100nM,
high dosage (10µM) ipomoeassin F saturates the binding pocket within only 10 min, which
significantly shorten screen time to 70min.

4.1.6. Procedure design for fluorescent probe based HTS research
Sharing the same target protein Sec61α, competition between ipomoeassin F and probe 4.1
are employed to isolate other compounds that hit the same target among large quantity of testing
compounds. Fluorescent intensity variation vividly reflects the binding dynamics, so within proper
work condition, the set of experiment enable potential application for HTS.
After systematic exploration, we found 1h treatment of probe 4.1 at 100nM work
concentration followed by 10 min 100-fold ipomoeassin F (or testing compound) incubation is a
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most suitable setting for the screening. As a result, procedure for fluorescent probe based HTS is
designed as follow:
Step 1. Seed MDA-MB-231 cells into 96-well plate.
Step 2. Treat cells with medium containing 10µM positive control ipomoeassin F, negative control
probe 4.2 and testing compound separately for 10min, followed by incubation with 100nM probe
4.1 for 1h in each group.
Step 3. Remove medium from each group and wash thoroughly with PBS for 3 times.
Step4. Collect fluorescent intensity reading from each group using plate reader at the optimized
excitation and emission setting.
Step5. Evaluate the test compound reading with positive control and negative control result.

4.1.7. Result interpretation
Because of the stable and strong fluorescent properties, probe 4.1 is considered as an ideal
candidate for target protein tracker. Solid result from positive control ipomoeassin F competition,
negative control 4.2 competition and co-stain with ER tracker point to the conclusion that probe
4.1 binds to target protein Sec61α and the binding could be competed off by active compound that
works on the identical binding site.
In the screening, fluorescent intensity from each test well represents the amount of 4.1 that
firmly binds to Sec61α. Test compound that possesses strong affinity with Sec61α may easily
compete off 4.1 like ipomoeassin F, leading to significant loss of fluorescent signal. Vice versa,
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low Sec61α affinity compound has little chance to compete 4.1 off, giving rise to large fluorescent
reading.
4.2.Biotin probe based HTS study
4.2.1. Mechanism for biotin probe based HTS research
Biotin modified probe 4.3 is proved to have specific binding with ER transmembrane protein
Sec61α, and its binding can be competed away by ipomoeassin F that target the same site. Like
the fluorescent probe based HTS study, proper condition and strategies for quantification would
enable this probe a valuable potential candidate for HTS.

Figure 4. 7. Structure of ipomoeassin F analogues 4.3.
Rather than generating detectable signal from the probe itself, 4.3 could excite secondary
signal by biotin affinity strategies. For protein visualization, antibody-based detection approach
western blot and ELISA are most commonly used due to the high sensitivity and specificity.
However, western blot is not a first consideration for high throughput screening due to the fussy
procedure. So, ELISA is applied to develop an easily accessible approach to effectively identify
Sec61α affinity compounds by biotin probe competition. Due to the limited time and restriction of
work condition, the following exploration for HTS application is designed for future work and
lack of supportive experimental data.
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4.2.2. HTS work condition optimization.
The Sec61α affinity compound screening is based on competition with probe 4.3 by using
active compound ipomoeassin F and negative compound 4.2 as reference. Hence, standardize the
work condition for competition and binding signal visualization is the key to perform HTS.
Firstly, the minimum ER microsome amount required for the screening will be evaluated to
make sure enough target protein would be detectable in the visualization step. Based on the
understanding of minimum number of ER microsome needed, the lowest work concentration C1
of 4.3 for clear and stable visualization will be explored. Next, the optimized 4.3 incubation time
T1 would be determined. In the following step, optimized competition fold difference F1 and its
competition time T2 for ipomoeassin F will be figured out. At last, since the commercial available
anti-biotin antibody coated ELISA is standardized, conjugated antibody work condition in ELISA
test will be optimized.

4.2.3. Procedure design for biotin probe based HTS research
In this project, our ultimate purpose is to quantitatively visualize the amount of 4.3 - Sec61α
complex with the help of enzyme conjugated antibody or radioactive antibody. The procedure of
biotin based HTS is listed as follow:
Step 1. Prepare sample as following
ER microsome is treated with positive control ipomoeassin F, negative control
probe 4.2 and testing compound separately at the concentration of C1*F1 for time T2,
followed by incubation with probe 4.3 at the concentration of C1 for time T1 in each
group. Then after multiple wash was performed in each group, n-dodecyl-ß-D-maltoside
(DDM) will be added into each group to disrupt ER membrane structure.
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Step 2. Add 100µl of sample from each group to anti-biotin polyclonal antibody coated 96 well
plate and incubate in room temperature for 2 h.
Step3. Wash plate thoroughly before adding anti-Sec61α mono clonal secondary enzyme
conjugated antibody and incubate in room temperature for 2h.
Step 4. Wash the plate thoroughly before adding substrate. Then read the plate after 0.5-1h room
temperature incubation.
Step 5. Evaluate the test compound reading with positive control and negative control result
A.
Enzyme conjugate
anti-Sec61α
antibody

Substrate

4.3-Sec61α
complex
Anti-biotin
antibody

B.

Controls

Samples

Figure 4. 8. Work flow of biotin-based HTS. (A) Elisa procedure diagram. (B) Testing result
diagram.
(diagrams
are
cited
from
http://ib.bioninja.com.au/options/untitled/b4medicine/elisa.html)
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4.2.4. Result interpretation
In the screening, cells are treated with high dosage ipomoeassin F, probe 4.2 and test
compound respectively. Positive control ipomoeassin F saturates Sec61α binding site in the high
concentration incubation, negative control does not consume any Sec61α binding site even in high
concentration. As a result, in the following incubation step, probe 4.3 is not able to bind Sec61α
in positive group but can freely bind Sec61α at its maximum capability. In this case, sample from
positive group contain little 4.3-Sec61α complex, while sample from negative group accumulate
relatively large amount of 4.3-Sec61α complex.
Since biotin is a key function group of 4.3, coating antibody can easily capture 4.3-Sec61α
in negative group but keeps little such complex in positive group. In the following steps, only
negative group would successfully bind enzyme conjugated antibody and catalyze substrate to
produce detectable signals. Therefore, the stronger signal suggests the lower binding affinity
between test compound and Sec61α, vice versa.
4.3.Conclusion
Sec61α is a critical ER transmembrane protein that play an indispensable role in protein
translocation. Applying HTS to identify natural product or synthetic compound that work on
Sec61α would provide abundant resources to develop anti-cancer drugs in medicinal chemistry.
Competition between probe 4.1 vs ipomoeassin F and probe 4.3 vs ipomoeassin F are well
established and based on their common binding protein Sec61α. Stable fluorescent property of
probe 4.1 enable its further potential application in HTS to search Sec61α high affinity compounds
by the comparation of ipomoeassin F competition. Albeit a lot of work need to be done, the great
sensitivity and easy accessibility endow the approach a promising future HTS. Unlike other probes,
when 4.3 specifically binds Sec61α, the core structure is buried inside the complex, sprouting the
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biotin group as a sticky end to provide extra binding site for ELISA quantitative visualization.
Competition from Sec61α high affinity compound is expected to be reflected on the ELISA
numerical reading, capacitating the potential application for ELISA-base HTS.
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SUMMARY AND CONCLUSIONS
Ipomeassin F is found to be one of promising natural products that would potentially curb
cancer neoplasia. In order to better understand the property of this newly developed compound,
we performed systematic SAR study and deep exploration on its MOA by using breast cancer
cell line MDA-MB-231 and MCF-7 as models.
Based on the complicated SAR study, we reveal that lipophilicity is vital to retain potency
of ipomoeassin F. Hydrophilic moieties in ipomoeassin F not only maintain the conformational
stability but also work as vessel to efficiently deliver the compound into cells from aqueous
environment. Impact significance of each group on ipomoeassin F potency is in the order of: DFucp >cinnamate >tiglate >alkene in cinnamate > alkene in tiglate > acetate > 3-OHFucp >cyclic skeleton ≈ ketone.
After treating cancer cells, ipomoeassin F would localize in ER and interact with the target
protein Sec61α by non-covalent binding or weak reversible covalent binding. The binding pocket
is deep inside the complex, and the firmly binding between ipomoeassin F and Sec61α requires
membrane environment to sustain stability.
By employing ipomoeassin F analogues which share same target Sec61α, potential
applications for Sec61α affinity compound HTS would be available. The application could be
either analyzed by fluorescent intensity analysis or biotin-based ELISA signal analysis.
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Appendix: Biosafety Approval Letter
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